GB2141425A - BBM-1675, A new antitumor antibiotic complex - Google Patents
BBM-1675, A new antitumor antibiotic complex Download PDFInfo
- Publication number
- GB2141425A GB2141425A GB08412368A GB8412368A GB2141425A GB 2141425 A GB2141425 A GB 2141425A GB 08412368 A GB08412368 A GB 08412368A GB 8412368 A GB8412368 A GB 8412368A GB 2141425 A GB2141425 A GB 2141425A
- Authority
- GB
- United Kingdom
- Prior art keywords
- bbm
- exhibits
- atcc
- strain
- methanol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003972 antineoplastic antibiotic Substances 0.000 title claims description 18
- 241000201778 Actinomadura verrucosospora Species 0.000 claims abstract description 36
- 230000003115 biocidal effect Effects 0.000 claims abstract description 16
- 230000000845 anti-microbial effect Effects 0.000 claims abstract description 12
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 233
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 95
- 150000001875 compounds Chemical class 0.000 claims description 58
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 52
- 239000002609 medium Substances 0.000 claims description 37
- 239000000741 silica gel Substances 0.000 claims description 37
- 229910002027 silica gel Inorganic materials 0.000 claims description 37
- 238000004809 thin layer chromatography Methods 0.000 claims description 37
- 238000000034 method Methods 0.000 claims description 34
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 33
- 239000002904 solvent Substances 0.000 claims description 32
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 31
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 30
- 208000032839 leukemia Diseases 0.000 claims description 30
- 239000000203 mixture Substances 0.000 claims description 30
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 29
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 24
- 238000012360 testing method Methods 0.000 claims description 23
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 22
- 229910052799 carbon Inorganic materials 0.000 claims description 22
- 238000004128 high performance liquid chromatography Methods 0.000 claims description 22
- 229910001868 water Inorganic materials 0.000 claims description 21
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 20
- 241000894006 Bacteria Species 0.000 claims description 18
- 241000699670 Mus sp. Species 0.000 claims description 18
- 238000006243 chemical reaction Methods 0.000 claims description 18
- 238000004519 manufacturing process Methods 0.000 claims description 18
- 229910052757 nitrogen Inorganic materials 0.000 claims description 18
- 206010028980 Neoplasm Diseases 0.000 claims description 17
- 230000002401 inhibitory effect Effects 0.000 claims description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 17
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 claims description 16
- 238000001228 spectrum Methods 0.000 claims description 16
- 230000008859 change Effects 0.000 claims description 15
- 239000001963 growth medium Substances 0.000 claims description 14
- 235000015097 nutrients Nutrition 0.000 claims description 14
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 claims description 14
- 238000000862 absorption spectrum Methods 0.000 claims description 13
- 230000001320 lysogenic effect Effects 0.000 claims description 12
- 238000010521 absorption reaction Methods 0.000 claims description 11
- 230000002441 reversible effect Effects 0.000 claims description 11
- 208000001382 Experimental Melanoma Diseases 0.000 claims description 10
- 230000003287 optical effect Effects 0.000 claims description 10
- GRONZTPUWOOUFQ-UHFFFAOYSA-M sodium;methanol;hydroxide Chemical compound [OH-].[Na+].OC GRONZTPUWOOUFQ-UHFFFAOYSA-M 0.000 claims description 10
- 229910052717 sulfur Inorganic materials 0.000 claims description 9
- 101150041968 CDC13 gene Proteins 0.000 claims description 8
- 241000233866 Fungi Species 0.000 claims description 8
- 229910052739 hydrogen Inorganic materials 0.000 claims description 8
- 238000002844 melting Methods 0.000 claims description 8
- 230000008018 melting Effects 0.000 claims description 8
- 244000005700 microbiome Species 0.000 claims description 8
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 claims description 7
- 229910021578 Iron(III) chloride Inorganic materials 0.000 claims description 7
- RJGDLRCDCYRQOQ-UHFFFAOYSA-N anthrone Chemical compound C1=CC=C2C(=O)C3=CC=CC=C3CC2=C1 RJGDLRCDCYRQOQ-UHFFFAOYSA-N 0.000 claims description 7
- 239000003153 chemical reaction reagent Substances 0.000 claims description 7
- WORJEOGGNQDSOE-UHFFFAOYSA-N chloroform;methanol Chemical compound OC.ClC(Cl)Cl WORJEOGGNQDSOE-UHFFFAOYSA-N 0.000 claims description 7
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 claims description 7
- FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 claims description 7
- 208000006552 Lewis Lung Carcinoma Diseases 0.000 claims description 6
- 241001465754 Metazoa Species 0.000 claims description 6
- 229910052760 oxygen Inorganic materials 0.000 claims description 6
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 5
- PBCJIPOGFJYBJE-UHFFFAOYSA-N acetonitrile;hydrate Chemical compound O.CC#N PBCJIPOGFJYBJE-UHFFFAOYSA-N 0.000 claims description 5
- 239000013078 crystal Substances 0.000 claims description 5
- FUKUFMFMCZIRNT-UHFFFAOYSA-N hydron;methanol;chloride Chemical compound Cl.OC FUKUFMFMCZIRNT-UHFFFAOYSA-N 0.000 claims description 5
- 230000014759 maintenance of location Effects 0.000 claims description 5
- 239000011593 sulfur Substances 0.000 claims description 5
- 239000002253 acid Substances 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 201000011510 cancer Diseases 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 208000015181 infectious disease Diseases 0.000 claims description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 4
- 239000001257 hydrogen Substances 0.000 claims 4
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 4
- 239000001301 oxygen Substances 0.000 claims 4
- 238000004949 mass spectrometry Methods 0.000 claims 2
- 239000008024 pharmaceutical diluent Substances 0.000 claims 2
- 238000000855 fermentation Methods 0.000 abstract description 29
- 230000004151 fermentation Effects 0.000 abstract description 29
- 230000000259 anti-tumor effect Effects 0.000 abstract description 20
- 239000003242 anti bacterial agent Substances 0.000 abstract description 11
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 63
- 230000000694 effects Effects 0.000 description 32
- 229920001817 Agar Polymers 0.000 description 26
- 239000008272 agar Substances 0.000 description 26
- 238000007912 intraperitoneal administration Methods 0.000 description 24
- 238000011282 treatment Methods 0.000 description 18
- 239000007787 solid Substances 0.000 description 17
- 239000000126 substance Substances 0.000 description 16
- 239000000523 sample Substances 0.000 description 15
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 14
- 230000000975 bioactive effect Effects 0.000 description 14
- DRSHXJFUUPIBHX-UHFFFAOYSA-N COc1ccc(cc1)N1N=CC2C=NC(Nc3cc(OC)c(OC)c(OCCCN4CCN(C)CC4)c3)=NC12 Chemical compound COc1ccc(cc1)N1N=CC2C=NC(Nc3cc(OC)c(OC)c(OCCCN4CCN(C)CC4)c3)=NC12 DRSHXJFUUPIBHX-UHFFFAOYSA-N 0.000 description 12
- ZYVSOIYQKUDENJ-WKSBCEQHSA-N chromomycin A3 Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@@H]1OC(C)=O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@@H](O)[C@H](O[C@@H]3O[C@@H](C)[C@H](OC(C)=O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@@H]1C[C@@H](O)[C@@H](OC)[C@@H](C)O1 ZYVSOIYQKUDENJ-WKSBCEQHSA-N 0.000 description 12
- 239000003981 vehicle Substances 0.000 description 12
- 241000187362 Actinomadura Species 0.000 description 11
- RURLVUZRUFHCJO-UHFFFAOYSA-N Chromomycin A3 Natural products COC(C1Cc2cc3cc(OC4CC(OC(=O)C)C(OC5CC(O)C(OC)C(C)O5)C(C)O4)c(C)c(O)c3c(O)c2C(=O)C1OC6CC(OC7CC(C)(O)C(OC(=O)C)C(C)O7)C(O)C(C)O6)C(=O)C(O)C(C)O RURLVUZRUFHCJO-UHFFFAOYSA-N 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 11
- 229920002472 Starch Polymers 0.000 description 10
- 238000007792 addition Methods 0.000 description 10
- 229940088710 antibiotic agent Drugs 0.000 description 10
- 239000002002 slurry Substances 0.000 description 10
- 239000008107 starch Substances 0.000 description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- 238000010828 elution Methods 0.000 description 9
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 8
- 210000002421 cell wall Anatomy 0.000 description 8
- 238000004587 chromatography analysis Methods 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 8
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 8
- 238000000746 purification Methods 0.000 description 8
- -1 D4ructose Chemical compound 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N DMSO Substances CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 7
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 7
- 235000010216 calcium carbonate Nutrition 0.000 description 7
- 229910000019 calcium carbonate Inorganic materials 0.000 description 7
- 150000002500 ions Chemical class 0.000 description 7
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 7
- 235000019698 starch Nutrition 0.000 description 7
- 235000000346 sugar Nutrition 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 229940041514 candida albicans extract Drugs 0.000 description 6
- 239000002054 inoculum Substances 0.000 description 6
- 239000000401 methanolic extract Substances 0.000 description 6
- XELZGAJCZANUQH-UHFFFAOYSA-N methyl 1-acetylthieno[3,2-c]pyrazole-5-carboxylate Chemical compound CC(=O)N1N=CC2=C1C=C(C(=O)OC)S2 XELZGAJCZANUQH-UHFFFAOYSA-N 0.000 description 6
- 239000008188 pellet Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 239000003643 water by type Substances 0.000 description 6
- 239000012138 yeast extract Substances 0.000 description 6
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
- PYMYPHUHKUWMLA-LMVFSUKVSA-N aldehydo-D-ribose Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 5
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 5
- 239000007943 implant Substances 0.000 description 5
- 239000002245 particle Substances 0.000 description 5
- 239000002689 soil Substances 0.000 description 5
- 241000894007 species Species 0.000 description 5
- 239000000758 substrate Substances 0.000 description 5
- UQZSVIGPZAULMV-DKWTVANSSA-N (2s)-2,4-diamino-4-oxobutanoic acid;propane-1,2,3-triol Chemical compound OCC(O)CO.OC(=O)[C@@H](N)CC(N)=O UQZSVIGPZAULMV-DKWTVANSSA-N 0.000 description 4
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 4
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 4
- HYPYXGZDOYTYDR-HAJWAVTHSA-N 2-methyl-3-[(2e,6e,10e,14e)-3,7,11,15,19-pentamethylicosa-2,6,10,14,18-pentaenyl]naphthalene-1,4-dione Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CC/C=C(C)/CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)=C(C)C(=O)C2=C1 HYPYXGZDOYTYDR-HAJWAVTHSA-N 0.000 description 4
- WTLKTXIHIHFSGU-UHFFFAOYSA-N 2-nitrosoguanidine Chemical compound NC(N)=NN=O WTLKTXIHIHFSGU-UHFFFAOYSA-N 0.000 description 4
- 238000005481 NMR spectroscopy Methods 0.000 description 4
- 239000004743 Polypropylene Substances 0.000 description 4
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 4
- 241000191967 Staphylococcus aureus Species 0.000 description 4
- 229940009456 adriamycin Drugs 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 4
- 239000007613 bennett's agar Substances 0.000 description 4
- 229910052681 coesite Inorganic materials 0.000 description 4
- 229910052906 cristobalite Inorganic materials 0.000 description 4
- 238000001704 evaporation Methods 0.000 description 4
- 230000008020 evaporation Effects 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- 229910052742 iron Inorganic materials 0.000 description 4
- 238000002955 isolation Methods 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 4
- 239000006877 oatmeal agar Substances 0.000 description 4
- 229920001155 polypropylene Polymers 0.000 description 4
- 239000004576 sand Substances 0.000 description 4
- 239000000377 silicon dioxide Substances 0.000 description 4
- 235000012239 silicon dioxide Nutrition 0.000 description 4
- 230000003595 spectral effect Effects 0.000 description 4
- 230000001954 sterilising effect Effects 0.000 description 4
- 238000004659 sterilization and disinfection Methods 0.000 description 4
- 229910052682 stishovite Inorganic materials 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 229910052905 tridymite Inorganic materials 0.000 description 4
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 4
- 235000019143 vitamin K2 Nutrition 0.000 description 4
- 239000011728 vitamin K2 Substances 0.000 description 4
- 229940041603 vitamin k 3 Drugs 0.000 description 4
- FCSKOFQQCWLGMV-UHFFFAOYSA-N 5-{5-[2-chloro-4-(4,5-dihydro-1,3-oxazol-2-yl)phenoxy]pentyl}-3-methylisoxazole Chemical compound O1N=C(C)C=C1CCCCCOC1=CC=C(C=2OCCN=2)C=C1Cl FCSKOFQQCWLGMV-UHFFFAOYSA-N 0.000 description 3
- 241000186361 Actinobacteria <class> Species 0.000 description 3
- 239000005695 Ammonium acetate Substances 0.000 description 3
- 101100005765 Arabidopsis thaliana CDF1 gene Proteins 0.000 description 3
- 101100007579 Arabidopsis thaliana CPP1 gene Proteins 0.000 description 3
- 229920002261 Corn starch Polymers 0.000 description 3
- 235000019733 Fish meal Nutrition 0.000 description 3
- 239000007836 KH2PO4 Substances 0.000 description 3
- 239000004809 Teflon Substances 0.000 description 3
- 229920006362 Teflon® Polymers 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 229940024606 amino acid Drugs 0.000 description 3
- 235000019257 ammonium acetate Nutrition 0.000 description 3
- 229940043376 ammonium acetate Drugs 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000002021 butanolic extract Substances 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 description 3
- 238000004440 column chromatography Methods 0.000 description 3
- 239000008120 corn starch Substances 0.000 description 3
- 238000000921 elemental analysis Methods 0.000 description 3
- NLFBCYMMUAKCPC-KQQUZDAGSA-N ethyl (e)-3-[3-amino-2-cyano-1-[(e)-3-ethoxy-3-oxoprop-1-enyl]sulfanyl-3-oxoprop-1-enyl]sulfanylprop-2-enoate Chemical compound CCOC(=O)\C=C\SC(=C(C#N)C(N)=O)S\C=C\C(=O)OCC NLFBCYMMUAKCPC-KQQUZDAGSA-N 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 239000004467 fishmeal Substances 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 239000011491 glass wool Substances 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 239000002198 insoluble material Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 238000001819 mass spectrum Methods 0.000 description 3
- 235000013379 molasses Nutrition 0.000 description 3
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 3
- 235000019796 monopotassium phosphate Nutrition 0.000 description 3
- 239000000049 pigment Substances 0.000 description 3
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 3
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 3
- 238000011218 seed culture Methods 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 230000003068 static effect Effects 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 229940035024 thioglycerol Drugs 0.000 description 3
- 239000007196 tryptone yeast extract agar Substances 0.000 description 3
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 2
- BBBFYZOJHSYQMW-LGDQNDJISA-N (2s)-2,4-diamino-4-oxobutanoic acid;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal Chemical compound OC(=O)[C@@H](N)CC(N)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O BBBFYZOJHSYQMW-LGDQNDJISA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- 235000014469 Bacillus subtilis Nutrition 0.000 description 2
- 125000006519 CCH3 Chemical group 0.000 description 2
- 241000222122 Candida albicans Species 0.000 description 2
- FKLJPTJMIBLJAV-UHFFFAOYSA-N Compound IV Chemical compound O1N=C(C)C=C1CCCCCCCOC1=CC=C(C=2OCCN=2)C=C1 FKLJPTJMIBLJAV-UHFFFAOYSA-N 0.000 description 2
- 241000221204 Cryptococcus neoformans Species 0.000 description 2
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- 241000192125 Firmicutes Species 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- 208000028018 Lymphocytic leukaemia Diseases 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241000544912 Melanoides Species 0.000 description 2
- 244000128833 Mimulus luteus Species 0.000 description 2
- 241000114093 Mucor flavus Species 0.000 description 2
- 102000016943 Muramidase Human genes 0.000 description 2
- 108010014251 Muramidase Proteins 0.000 description 2
- 241000186359 Mycobacterium Species 0.000 description 2
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 2
- 229910002651 NO3 Inorganic materials 0.000 description 2
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- 239000001888 Peptone Substances 0.000 description 2
- 108010080698 Peptones Proteins 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- WURKLEUBADSHTC-AJVJTBPOSA-N [(2s,3s,4s,6s)-6-[(2r,3r,4r,6s)-6-[(2r,3r,4r,6s)-6-[[(2s,3s)-6-[(2s,4r,5s,6r)-4-acetyloxy-5-[(2r,4r,5r,6r)-4-hydroxy-5-methoxy-6-methyloxan-2-yl]oxy-6-methyloxan-2-yl]oxy-3-[(1s,3s,4r)-3,4-dihydroxy-1-methoxy-2-oxopentyl]-8,9-dihydroxy-1-oxo-3,4-dihydro-2 Chemical compound O([C@@H]1[C@H](OC(C)=O)C[C@@H](O[C@@H]1C)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@@H](O)[C@H](O[C@@H]3O[C@@H](C)[C@H](OC(=O)C(C)C)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@@H]1C[C@@H](O)[C@@H](OC)[C@@H](C)O1 WURKLEUBADSHTC-AJVJTBPOSA-N 0.000 description 2
- 238000005273 aeration Methods 0.000 description 2
- PNNNRSAQSRJVSB-BXKVDMCESA-N aldehydo-L-rhamnose Chemical compound C[C@H](O)[C@H](O)[C@@H](O)[C@@H](O)C=O PNNNRSAQSRJVSB-BXKVDMCESA-N 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 239000004599 antimicrobial Substances 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 238000004166 bioassay Methods 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 229940125904 compound 1 Drugs 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 229910000366 copper(II) sulfate Inorganic materials 0.000 description 2
- YPHMISFOHDHNIV-FSZOTQKASA-N cycloheximide Chemical compound C1[C@@H](C)C[C@H](C)C(=O)[C@@H]1[C@H](O)CC1CC(=O)NC(=O)C1 YPHMISFOHDHNIV-FSZOTQKASA-N 0.000 description 2
- 239000012225 czapek media Substances 0.000 description 2
- 230000006866 deterioration Effects 0.000 description 2
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 2
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 2
- 235000019797 dipotassium phosphate Nutrition 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 235000019441 ethanol Nutrition 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 2
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 2
- 238000005984 hydrogenation reaction Methods 0.000 description 2
- 229960000367 inositol Drugs 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 208000003747 lymphoid leukemia Diseases 0.000 description 2
- 239000004325 lysozyme Substances 0.000 description 2
- 235000010335 lysozyme Nutrition 0.000 description 2
- 229960000274 lysozyme Drugs 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 230000000877 morphologic effect Effects 0.000 description 2
- 239000006916 nutrient agar Substances 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 235000019319 peptone Nutrition 0.000 description 2
- 239000002798 polar solvent Substances 0.000 description 2
- CASUWPDYGGAUQV-UHFFFAOYSA-M potassium;methanol;hydroxide Chemical compound [OH-].[K+].OC CASUWPDYGGAUQV-UHFFFAOYSA-M 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 2
- 238000001004 secondary ion mass spectrometry Methods 0.000 description 2
- 239000012279 sodium borohydride Substances 0.000 description 2
- 229910000033 sodium borohydride Inorganic materials 0.000 description 2
- VWDWKYIASSYTQR-UHFFFAOYSA-N sodium nitrate Chemical compound [Na+].[O-][N+]([O-])=O VWDWKYIASSYTQR-UHFFFAOYSA-N 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 241001446247 uncultured actinomycete Species 0.000 description 2
- 239000011800 void material Substances 0.000 description 2
- GMKMEZVLHJARHF-UHFFFAOYSA-N (2R,6R)-form-2.6-Diaminoheptanedioic acid Natural products OC(=O)C(N)CCCC(N)C(O)=O GMKMEZVLHJARHF-UHFFFAOYSA-N 0.000 description 1
- PJVXUVWGSCCGHT-GGJBBHSUSA-N (2r,3s,4s,5r)-2,3,4,5,6-pentahydroxyhexanal;(3s,4r,5r)-1,3,4,5,6-pentahydroxyhexan-2-one Chemical compound OC[C@@H](O)[C@H](O)[C@H](O)[C@@H](O)C=O.OC[C@@H](O)[C@@H](O)[C@H](O)C(=O)CO PJVXUVWGSCCGHT-GGJBBHSUSA-N 0.000 description 1
- RMTFNDVZYPHUEF-JRTVQGFMSA-N (2r,3s,4s,5r)-2,4,5,6-tetrahydroxy-3-methoxyhexanal Chemical compound O=C[C@H](O)[C@@H](OC)[C@@H](O)[C@H](O)CO RMTFNDVZYPHUEF-JRTVQGFMSA-N 0.000 description 1
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 1
- HORQAOAYAYGIBM-UHFFFAOYSA-N 2,4-dinitrophenylhydrazine Chemical compound NNC1=CC=C([N+]([O-])=O)C=C1[N+]([O-])=O HORQAOAYAYGIBM-UHFFFAOYSA-N 0.000 description 1
- PAWQVTBBRAZDMG-UHFFFAOYSA-N 2-(3-bromo-2-fluorophenyl)acetic acid Chemical compound OC(=O)CC1=CC=CC(Br)=C1F PAWQVTBBRAZDMG-UHFFFAOYSA-N 0.000 description 1
- 229910000619 316 stainless steel Inorganic materials 0.000 description 1
- FDWRIIDFYSUTDP-UHFFFAOYSA-N 6-methyloxane-2,4,5-triol Chemical group CC1OC(O)CC(O)C1O FDWRIIDFYSUTDP-UHFFFAOYSA-N 0.000 description 1
- 241000201753 Actinomadura coerulea Species 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- 238000009631 Broth culture Methods 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 241000193468 Clostridium perfringens Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- GUBGYTABKSRVRQ-CUHNMECISA-N D-Cellobiose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-CUHNMECISA-N 0.000 description 1
- RFSUNEUAIZKAJO-VRPWFDPXSA-N D-Fructose Natural products OC[C@H]1OC(O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-VRPWFDPXSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- QWIZNVHXZXRPDR-UHFFFAOYSA-N D-melezitose Natural products O1C(CO)C(O)C(O)C(O)C1OC1C(O)C(CO)OC1(CO)OC1OC(CO)C(O)C(O)C1O QWIZNVHXZXRPDR-UHFFFAOYSA-N 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- YXHKONLOYHBTNS-UHFFFAOYSA-N Diazomethane Chemical compound C=[N+]=[N-] YXHKONLOYHBTNS-UHFFFAOYSA-N 0.000 description 1
- 241001269524 Dura Species 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 238000003820 Medium-pressure liquid chromatography Methods 0.000 description 1
- 229910017621 MgSO4-7H2O Inorganic materials 0.000 description 1
- RMTFNDVZYPHUEF-UHFFFAOYSA-N O3-methyl-D-galactose Natural products O=CC(O)C(OC)C(O)C(O)CO RMTFNDVZYPHUEF-UHFFFAOYSA-N 0.000 description 1
- PJVXUVWGSCCGHT-HJYCITFRSA-N OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O.OC[C@H](O)[C@@H](O)[C@H](O)C(=O)CO Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O.OC[C@H](O)[C@@H](O)[C@H](O)C(=O)CO PJVXUVWGSCCGHT-HJYCITFRSA-N 0.000 description 1
- MXETZQATVMJCFH-UHFFFAOYSA-N Olivomycin A Natural products COC(C1Cc2cc3cc(OC4CC(OC(=O)C)C(OC5CC(O)C(OC)C(C)O5)C(C)O4)cc(O)c3c(O)c2C(=O)C1OC6CC(OC7CC(OC8CC(C)(O)C(OC(=O)C(C)C)C(C)O8)C(O)C(C)O7)C(O)C(C)O6)C(=O)C(O)C(C)C MXETZQATVMJCFH-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- 239000006159 Sabouraud's agar Substances 0.000 description 1
- NGFMICBWJRZIBI-JZRPKSSGSA-N Salicin Natural products O([C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O1)c1c(CO)cccc1 NGFMICBWJRZIBI-JZRPKSSGSA-N 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 241000187747 Streptomyces Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 239000003929 acidic solution Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 238000012459 agar diffusion assay Methods 0.000 description 1
- 238000002814 agar dilution Methods 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 238000005904 alkaline hydrolysis reaction Methods 0.000 description 1
- 239000012670 alkaline solution Substances 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- SRBFZHDQGSBBOR-MBMOQRBOSA-N alpha-D-arabinopyranose Chemical compound O[C@@H]1CO[C@H](O)[C@@H](O)[C@@H]1O SRBFZHDQGSBBOR-MBMOQRBOSA-N 0.000 description 1
- NGFMICBWJRZIBI-UHFFFAOYSA-N alpha-salicin Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=CC=C1CO NGFMICBWJRZIBI-UHFFFAOYSA-N 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 239000012296 anti-solvent Substances 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000007640 basal medium Substances 0.000 description 1
- 150000007514 bases Chemical class 0.000 description 1
- SRBFZHDQGSBBOR-KLVWXMOXSA-N beta-L-arabinopyranose Chemical compound O[C@H]1CO[C@H](O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-KLVWXMOXSA-N 0.000 description 1
- DLRVVLDZNNYCBX-ZZFZYMBESA-N beta-melibiose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O)O1 DLRVVLDZNNYCBX-ZZFZYMBESA-N 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 235000013877 carbamide Nutrition 0.000 description 1
- 230000025938 carbohydrate utilization Effects 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 150000001793 charged compounds Chemical class 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- OQNGCCWBHLEQFN-UHFFFAOYSA-N chloroform;hexane Chemical compound ClC(Cl)Cl.CCCCCC OQNGCCWBHLEQFN-UHFFFAOYSA-N 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- 238000011097 chromatography purification Methods 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 238000013501 data transformation Methods 0.000 description 1
- 230000000249 desinfective effect Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- PXEDJBXQKAGXNJ-QTNFYWBSSA-L disodium L-glutamate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](N)CCC([O-])=O PXEDJBXQKAGXNJ-QTNFYWBSSA-L 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- FBPFZTCFMRRESA-GUCUJZIJSA-N galactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-GUCUJZIJSA-N 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000005227 gel permeation chromatography Methods 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229940069016 go-dry Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 238000012750 in vivo screening Methods 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 238000003760 magnetic stirring Methods 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 231100000682 maximum tolerated dose Toxicity 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 230000000684 melanotic effect Effects 0.000 description 1
- GMKMEZVLHJARHF-SYDPRGILSA-N meso-2,6-diaminopimelic acid Chemical compound [O-]C(=O)[C@@H]([NH3+])CCC[C@@H]([NH3+])C([O-])=O GMKMEZVLHJARHF-SYDPRGILSA-N 0.000 description 1
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Natural products C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 1
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 1
- QQFHCCQSCQBKBG-UHFFFAOYSA-N methyl 2-amino-4,5-dimethoxybenzoate Chemical compound COC(=O)C1=CC(OC)=C(OC)C=C1N QQFHCCQSCQBKBG-UHFFFAOYSA-N 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- KELXKDDAALYTDI-BTVCFUMJSA-N nitric acid;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal Chemical compound O[N+]([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O KELXKDDAALYTDI-BTVCFUMJSA-N 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- OCOLTXUAPMAMPP-AJVJTBPOSA-N olivomycin A Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@@H]1OC(C)=O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@@H](O)[C@H](O[C@@H]3O[C@@H](C)[C@H](OC(=O)C(C)C)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@@H]1C[C@@H](O)[C@@H](OC)[C@@H](C)O1 OCOLTXUAPMAMPP-AJVJTBPOSA-N 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 125000001477 organic nitrogen group Chemical group 0.000 description 1
- 239000000123 paper Substances 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002953 preparative HPLC Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 239000012521 purified sample Substances 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000012449 sabouraud dextrose agar Substances 0.000 description 1
- 229940120668 salicin Drugs 0.000 description 1
- 230000002784 sclerotic effect Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 235000010344 sodium nitrate Nutrition 0.000 description 1
- 239000004317 sodium nitrate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- CMXPERZAMAQXSF-UHFFFAOYSA-M sodium;1,4-bis(2-ethylhexoxy)-1,4-dioxobutane-2-sulfonate;1,8-dihydroxyanthracene-9,10-dione Chemical compound [Na+].O=C1C2=CC=CC(O)=C2C(=O)C2=C1C=CC=C2O.CCCCC(CC)COC(=O)CC(S([O-])(=O)=O)C(=O)OCC(CC)CCCC CMXPERZAMAQXSF-UHFFFAOYSA-M 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 238000010183 spectrum analysis Methods 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 230000001550 time effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- YWYZEGXAUVWDED-UHFFFAOYSA-N triammonium citrate Chemical compound [NH4+].[NH4+].[NH4+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O YWYZEGXAUVWDED-UHFFFAOYSA-N 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P1/00—Preparation of compounds or compositions, not provided for in groups C12P3/00 - C12P39/00, by using microorganisms or enzymes
- C12P1/02—Preparation of compounds or compositions, not provided for in groups C12P3/00 - C12P39/00, by using microorganisms or enzymes by using fungi
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
- C07H13/02—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
- C07H13/08—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals directly attached to carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H11/00—Compounds containing saccharide radicals esterified by inorganic acids; Metal salts thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P1/00—Preparation of compounds or compositions, not provided for in groups C12P3/00 - C12P39/00, by using microorganisms or enzymes
- C12P1/06—Preparation of compounds or compositions, not provided for in groups C12P3/00 - C12P39/00, by using microorganisms or enzymes by using actinomycetales
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- General Chemical & Material Sciences (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Mycology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Engineering & Computer Science (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Compounds Of Unknown Constitution (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Saccharide Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
An antibiotic complex designated herein as BBM-1675 complex is produced by fermentation of certain novel strains of Actinomadura verrucosospora. The complex may be separated into two major components, BBM-1675A1 and A2, and four minor components, BBM-1675 A3, A4, B1 and B2, and such components exhibit both antimicrobial activity and antitumor activity.
Description
SPECiFICATION
BBM-1675, a new antitumor antibiotic complex
Background of the invention
1. Field of the invention
This invention relates to new antitumor antibiotic substances and to their production and recovery.
2. Description of the prior art
The antitumor antibiotic compounds of the present invention have not yet been identified in terms of
structure. In view of their unique physical, chemical and biological properties, however, applicants believe that the BBM-1675 antibiotics are novel substances.
European Patent Publication No. 95154A1 discloses fermentation of Actinomadura pulveraceus sp. nov.
No. 6049 (ATCC 39100) to produce antitumor antibiotics designated WS 6049-A and WS 6049-B. The
structures of the WS 6049 antibiotics have not yet been elucidated, but the characterizing properties given for the antibiotics indicate that WS 6049-A and WS 6049-B may be related in structure to the BBM-1675
antibiotics of the present invention. Spectral data show, however, that neither WS 6049A nor WS 6049B is
identical to any of applicants' BBM-1675 components. Moreover, the producing organism described in
European Patent Application Publication No. 95154A1 may be clearly differentiated from Actinomadura
verrucosospora employed in the present invention in the color of its aerial mycelium on ISP Medium Nos. 2, 3 and 4, in its positive milk peptonization and in its positive utilization of D-fructose, D-mannitol, trehalose
and cellulose.
Summary of the invention
There is provided by the present invention a new antitumor antibiotic complex designated herein as
BBM-1675, said complex being produced by cultivating a BBM-1675-producing strain of Actinomadura
verrucosospora most preferablyActinomadura verrucosospora strain H964-92 (ATCC 39334) orActinoma
dura verrucosospora strain A1327Y (ATCC 39638), or a mutant thereof, in an aqueous nutrient medium containing assimilable sources of carbon and nitrogen under submerged aerobic conditions until a substantial amount of said BBM-1675 complex is produced by said organism in said culture medium, and optionally recovering the complex from the culture medium.Also provided by the present invention are two
major bioactive components of BBM-1675 complex designated as BBM 1675A1 and A2 and four minor
bioactive components of said complex designated BBM-1 675A3, A4, B1 and B2. The components may be separated and purified by conventional chromatographic procedures. The BBM-1675 complex and its
bioactive components exhibit both antimicrobial and antitumor activity.
Description ofthe drawings
Figure 1 shows the infrared absorption spectrum of partially purified BBM-1675 A1 (KBr pellet).
Figure 2 shows the infrared absorption spectrum of partially purified BBM-1 675 A2 (KBr pellet).
Figure 3 shows the infrared absorption spectrum of B BBM-1675 A3 (KBr pellet).
Figure 4 shows the infrared absorption spectrum of BBM-1675 A4 (KBr pellet).
Figure 5 shows the proton magnetic resonance spectrum of partially purified BBM-1675 A1 in CDC13 (60
MHz).
Figure 6 shows the proton magnetic resonance spectrum of partially purified BBM-1675 A2 in CDCl3 (60
MHz).
Figure 7 shows the proton magnetic resonance spectrum of BBM-1675 A3 in CDC13 (60 MHz).
Figure 8 shows the proton magnetic resonance spectrum of BBM-1675 A4 in CDC13 (60 MHz).
Figure 9 shows the infrared absorption spectrum of purified BBM-1 675 A1 (KBr pellet).
Figure 10 shows the proton magnetic resonance spectrum of purified BBM-1675 A1 in CDC13 (360 MHz).
Figure 11 shows the 13c magnetic resonance spectrum of purified BBM-1675 A1 in CDC13 (90.3 MHz).
Figure 12 shows the infrared absorption spectrum of purified BBM-1675 A2 (KBr pellet).
Figure 13 shows the proton magnetic resonance spectrum of purified BBM-1 675 A2 in CDC13 (360 MHz).
Figure 14 shows the 13C magnetic resonance spectrum of purified BBM-1 675 A2 in CDCI3 (90.3 MHz).
Detailed description
This invention relates to a novel antitumor antibiotic complex designated herein as BBM-1675 and to its preparation by fermentation of certain strains of Actinomadura verrucosospora, most particularly
Actinomadura verrucosopora strain H964-92 and a mutant thereof designated Actinomadura verrucosospora strain A1327Y. The above-mentioned parent strain was isolated from a soil sample collected at Pto
Esperanza, Misiones, Argentina. A biologically pure culture of the organism has been deposited (28th March, 1983) with the American Type Culture Collection, Washington, D.C. and added to its permanent collection of microorganisms as ATCC 39334.Subsequently, the mutant strain A1327Y was obtained by conventional nitrosoguanidine (NTG) treatment of strain H964-92 and was deposited with the American Type Culture
Collection as ATCC 39638 on 21st March, 1984.
As in the case of many antibiotic-producing cultures, fermentation of Actinomadura verrucosospora strain
H964-92 or strain A1327Y results in the production of a mixture or complex of component substances. Two major bioactive components, BBM-1675 A1 and A2, and four minor bioactive components, BBM-1675 A3, A4,
B1 and B2, have been separated from the BBM-1675 complex produced during the fermentation process.
BBM-1675 and its components BBM-1675 A1, A2, A3, A4, B1 and B2 exhibit antimicrobial activity against a broad spectrum of microorganisms including especially gram-positive bacteria. The BBM-1675 complex and separated bioactive components thereof also exhibit phage inducing properties in lysogenic bacteria. Two of the components, BBM-1675 A1 and A2, have been submitted to in vivo screening against various mouse tumor systems and demonstrate inhibitory activity against L-1210 leukemia, P-388 leukemia, B16 melanoma and Lewis lung carcinoma. BBM-1675 A3 and A4 have been shown to exhibit activity against mouse P-388 leukemia. The complex and its bioactive components, therefore, may be used as antimicrobial agents or as antitumor agents for inhibiting mammalian tumors.
The microorganism
The actinomycete Strain No. H964-92 was isolated from a soil sample and prepared by conventional procedures as a biologically pure culture for characterization. Strain H964-92 forms on the aerial mycelium short spore-chains which show straight, flexuous or hooked shapes. The spores are spherical or oval-shaped and have a warty surface. Aerial mycelium is poorly formed on most media. The aerial mass color is white which later turns to a pinkish shade, or further changes to a bluish color in some agar media. The color of substrate mycelium is colorless or pale pink. The growth temperature ranges from 15"C to 430C.The cell-wall amino acid composition and whole cell hydrolyzate sugar components show that strain H964-92 belongs to cell wall Type Ills. The menaquinone was identified as MK-9(H6) MK-9(H8).
Based on the major morphological, cultural and physiological characteristics along with the chemical cell-wall composition characteristics, strain H964-92 can be classified as belonging to the genus
Actinomadura.
Although the original strain H964-92 gave only moderate growth and bore scant aerial mycelia, a variant showing good growth and improved aerial mycelium formation was obtained by NTC (nitrosoguanidine) treatment of H964-92. The variant, designated strain A1327Y, facilitated further taxonomical investigation and was subsequently identified as Actinomadura verrucosospora.
Methods
The media and procedures used for examining cultural characteristics and carbohydrate utilization were those recommended by the International Streptomyces Project (Inc. J. Syst Bacterial 16: 313-340, 1966).
Additional media described by S. A. Waksman (TheActinomycetes, Vol. 2) and G. M. Lvedemann (Int J.
Syst Bacteriol. 21: 240-247, 1971)were also used. The cell wall-amino acid composition and whole cell hydrolyzate sugar components were analyzed according to the methods described by Becker, et al. in Appl.
Microbiol. 13: 236-243, 1965 and by Lechevalier and Lechevalier in TheActinomycetes, Ed. H. Prauser, Jena,
Gustav Fischer Verlag, pp. 393-405, 1970, respectively. The menaquinone was identified by mass spectral analysis according to the procedure of Collins et al. in J. Gen. Microbiol. 100: 221-230, 1977, and the menaquinone composition was represented based on the system described by Yamada et al. in J. Gen. Appi.
Micrnbiol 23: 331-335, 1977.
Morphology
Strain H964-2 forms both substrate and aerial mycelia. The substrate mycelium is long, branched and not fragmented into short filaments. In the aerial mycelium, short spore-chains are formed monopodially or at the hyphal tip. Whorl-like branches of spore-chain are also observed nearby the hyphal tip. These spore-chains contain 2 to 10 spores in a chain and are straight, flexuous or hooked in shape. The spores have a warty surface and are spherical to elliptical (0.5-0.6 x 0.6-1.4 Am) in shape with rounded or pointed ends.
After maturation each spore is often separated with empty sheath. Motile spores, sporangia or sclerotic granules are not seen in any media examined.
Cultural and physiological characteristics
Growth of strain H964-92 is poor to moderate in both chemically defined media and natural organic media.
Formation of aerial mycelium is generally poor but is moderate in oat meal agar (ISP No. 3 medium), inorganic salts-starch agar (ISP No. 4 medium) and Bennett's agar. Spontaneous variants which lack aerial mycelium occur at high frequency. The color of aerial mycelium is white which later turns to pale pink in oat meal agar, inorganic salts-starch agar and glycerol-asparagine agar (ISP No. 5 medium). The aerial mass colorfurther changes to a bluish color after long incubation (5 months) in oat meal agar, glycerol-asparagine agar and tyrosine agar. The color of substrate mycelium is colorless to yellowish in Czapek's agar, tyrosine agar, yeast extract-malt extract agar (ISP No. 2 medium), peptone-yeast extract-iron agar (ISP No. 6 medium) and Bennett's agar, and is a pinkish color in glucose-asparagine agar and glycerol-asparagine agar.
Melanoid and other diffusible pigments are not produced. A variant No. A1327Y, which was obtained from the original strain, forms predominantly pale blue aerial mycelium and bears abundant aerial spore mass.
Strain H964-92 grows at 1 5 C, 280C, 37"C and 43"C, but not at 10C or at 47"C. It is sensitive to NaCI at 7%, and resistant to lysozyme at 0.01%.
The cultural and physiological characteristics of the producing strain are shown in Tables 1 and 2, respectively. The utilization of carbon sources is shown in Table 3.
TABLE 1
Cultural Characteristics of Strain H964-92
(original strain A TCC 39334 and variant A 1327Y) Strain No. H964-92
Actinomadura
Original Strain verrucosospora (A TCC 39334) Variant No. A 1327Y KCCA-0147
Tryptone-yeast extract G: abundant, floccose, moderate, floccose, moderate, floccose, agar (ISP No. 1) sedimented and not sedimented and not sedimented and not
pigmented pigmented pigmented
Sucrose-nitrateagar G: moderate poor poor (Czapek's agar) R: colorless colorless colorless
A: scant; light gray no or scant; pinkish no or scant; pale
(264), to pale pink white (9) blue (185)
(7)
D: none none none
Glucose-asparagine agar G: moderate poor poor
R: white (263) to deep colorless colorless
yellowish pink (277)
A: no or very scant; no or very scant; no or very scant;
pale pink (7) white white
D:none none none
Glycerol-asparagine agar G: poor to moderate moderate moderate (ISP No. 5) R: colorless to light light yellowish light yellowish pink
yellowish pink (28) pink (28) (28 to deep yellow
ish pink (27)
A: poor; light yellow- moderate; white to moderate; white to
ish pink (28), after light pink (4) strong pink (2)
5 months light
bluish gray (190)
D: none none none Inorganicsalts-starch G: abundant moderate moderate agar (ISP No. 4) R: yellowish white light yellowish pink light yellowish pink
(92) (28) (28)
A: abundant; light pink moderate; light bluish abundant; pale blue
(4)to pinkish gray gray(190) (185)
(10)
D: none none none
Tyrosineagar G: moderate moderate moderate (ISP No.7) R: yellowish white (92) strong yellowish pink strong yellowish
(26) pink (26)
A: poor; light yellow- moderate;white to moderate; white to
ish pink (28), very light pink (4) light pink (4)
later (5 months)
partially light bluish
gray (190)
D: none none none
Nutrient agar G: poorto moderate poor poor
R: pale yellow (89) colorless to pale colorless to pale
pink(7) pink(7)
A: none none none
D: none none none
TABLE 1 - cont'd
Strain No. H964-92
Actinomadura
Original Strain verrucosospora
(A TCC39334) Variant No.A 1327Y KCCA-0147
Yeast extract-malt G: abundant abundant abundant extract agar R: pale yellow (89) strong yellowish strong yellowish (ISP No.2) pink (26) pink (26)
A: poor; white (263) poor; white to pale poor; white to pale
pink (7) pink (7)
D: none none none
Oat meal agar G: moderate poor poor (ISP No.3) R: colorless to pale pale yellowish pale yellowish
pink (7) pink(31) pink (31)
A: poor; pinkish very scant; vivid very scant; vivid
white (9) to light pale blue (184) pale blue (184)
bluish gray (190)
D: none none none
Bennett's agar G: abundant abundant abundant
R: grayish yellow (90) strong yellowish strong yellowish
pink (26) pink (26)
A: moderate; white (263) moderate; pale yellow- none
to yellowish white ish pink (31) and
(92) bluish white (189)
D: none none none Peptone-yeast extract- G: moderate abundant abundant iron agar (ISP No. 6) R: colorless colorless colorless
A: none none none
D: none none none
* Observed after incubation at 37"C for 3 weeks.
** Abbreviation: G = Growth; R = Reverse color; A = Aerial mycelium; D = Diffusible pigment Color and number in parenthesis follow the color standard in "Kelly, K. L. & D. B. Judd; ISCC-NBS color-name charts illustrated with Centroid Colors. U.S. Dept. of Comm. Cir. 553, Washington, D.C., Nov.,
1975".
KCC = Kaken Culture Collection of Kaken Chemical Company
TABLE 2
Physiological Characteristics of Strain H964-92
Test Response Method and Medium
Range of temperature Maximal growth at Bennett's agar for growth 28"C to 37"C.
Moderate at 20"C and 43"C. No growth
at 10"C and 47"C.
Gelatin liquefaction Liquefied Glucose-peptone-gelatin medium
Starch hydrolysis Hydrolyzed Starch agar plate
Reactions in skimmed Not coagulated Difco skimmed milk milk and completely
peptonized
Formation of melanoid Not produced Tyrosin agar, peptone-yeastpigment iron agar and tryptone-yeast
extract broth.
Nitrate reduction Not reduced Czapek's glucose-nitrate broth
and glucose-yeast extract
nitrate broth
Resistance to NaCI Growth at 5% or Tryptone-yeast extract agar
less. No growth
at 7%.
Lysozyme Resistant. Growth Tryptone-yeast extract agar
at 0.01% or less.
No growth at 0.1%.
pH Growth in 5.0 to Tryptone-yeast extract agar
9.5. No growth
at 4.5 and 10.0.
TABLE 3
Utilization of Carbon Sources
Strain No, H964-92 Actinomadura
Original Variant verrucosospora
strain No. A 1327Y KCC A-0147
Glycerol + + +
D(-)-Arabinose -
L(+)-Arabinose + + +
D-Xylose + + +
D-Ribose +
L-Rhamnose + + +
D-Glucose + + +
D-Galactose -
D-Fructose + + +
D-Mannose - L(-)-Sorbose Sucrose + + +
Lactose - - Cellobiose + + +
Melibiose -
Trehalose + + +
Raffinose - D(+)-Melezitose Soluble starch + + +
Cellulose + + +
Dulcitol - - Inositol + - D-Mannitol + + +
D-Sorbitol -
Salicin -
Observed after incubation at 28"C for 3 weeks
Basal medium:Pridham-Gottlieb inorganic medium
Cell-wall composition and whole cell sugar components
Purified cell-wall of strain H964-92 contains mesodiaminopimelic acid but lacks glycine. The whole cell hydrolyzate shows the presence of madurose (3-O-methyl-D-galactose), glucose and ribose. The cell-wall amino acid and whole cell sugar components indicate that strain H964-92 is placed in cell-wall Type lllB. Two major components of menaquinone were identified as MK-9(H6) and MK-9(H8).
Taxonomic position ofstrain H964-92
Strain H964-92 has the following major characteristics: (1) Aerial spore-chains: short, straight, flexuous or hooked in shape. (2) Spores: warty surface. (3) Aerial mycelium: pinkish or bluish color. (4) Substrate mycelium: pinkish in some media. (5) Diffusible pigment: none. (6) Mesophile. (7) Cell-wall Type Ills. (8) Menaquinonesystem: MK-9(H6) and MK-9(H8).
These major characteristics indicate that strain H964-92 is placed in the genusActinomadura. Early species of the genus Actinomadura were isolated from mammals. Some strains were also obtained from plant materials. However, many of the new species proposed recently were isolated from soil. According to the numerical taxonomy and review of theActinomadura and related actinomycetes by Goodfellow et al. in J.
Gen. Microbiol. 112: 96-111 (1979), most Actinomadura species of soil origin are classified into Cluster No. 7 among the 14 clusters described. Strain No. H964-92 is most related to the species of Cluster 7. Nonomura and Ohara in J. Ferment Technol. 49: 904-912 (1971) reported five saprophytic species of the genus
Actinomadura and Nonomura [J. Ferment Technol. 52:71-77(1974)] and Preobrazhenskaya petal.
[Actinomycetes and Related Organisms 12: 30-38 (1977)] published the keys for identification and classification of the Actinomadura species. As a result of comparison with the descriptions of 30 species including organisms disclosed in patents, strain H964-92 appears most similar to Actinomadura coerulea described in the Preobrazhenskaya et al. reference above and to Actinomadura verrucosospora described in the Nonomura references cited above.
Strain No. H964-92 was directly compared with A. verrucosospora strain KCC A-01 47 and was found to be closely related to A. verrucosospora in the morphological, cultural and physiological characteristics. Thus, strain H964-92 is classified as a new strain of Actinomadura verrucosospora.
It is to be understood that for the production of BBM-1675, the present invention, though described in detail with reference to the particular strain Actinomadura verrucosospora strain H964-92 (ATCC 39334) and the mutant strain thereof designated strain A1327Y (ATCC 39638), is not limited to these microorganisms or to microorganisms fully described by the cultural characteristics disclosed herein. It is specifically intended that the invention embrace strain H964-92 and all natural and artificial BBM-1675-producting variants and mutants thereof.
Antibiotic production
The BBM-1675 antibiotics of the present invention may be prepared by cultivating a BBM-1675-producing strain of Actinomadura verrucosospora, preferably a strain ofActinomadura verrucosospora having the identifying characteristics of ATCC 39334 or ATCC 39638, or a mutant thereof, in a conventional aqueous nutrient medium. The organism is grown in a nutrient medium containing known nutritional sources for actinomycetes, i.e. assimilable sources of carbon and nitrogen plus optional inorganic salts and other known growth factors. Submerged aerobic conditions are preferably employed for the production of large quantities of antibiotics, although for production of limited amounts, surface cultures and bottles may also be used. The general procedures used for the cultivation of other actinomycetes are applicable to the present invention.
The nutrient medium should contain an appropriate assimilable carbon source such as glycerol, L(+)-arabinose, D-xylose, D-ribose, L-rhamnose, D-glucose, D4ructose, sucrose, cellobiose, soluble starch,
D-mannitol or inositol. As nitrogen sources, ammonium chloride, ammonium sulfate, urea, ammonium nitrate, sodium nitrate, etc. may be used either alone or in combination with organic nitrogen sources such as peptone, meat extract, yeast extract, corn steep liquor, soybean powder, cotton seed flour, etc. There may also be added, if necessary, nutrient inorganic salts to provide sources of sodium, potassium, calcium, ammonium, phosphate, sulfate, chloride, bromide, carbonate, zinc, magnesium, manganese, cobalt, iron, and the like.
Production of the BBM-1 675 antibiotics can be effected at any temperature conducive to satisfactory growth of the producing organism, e.g. 15-45"C, and is conveniently carried out at a temperature of around 27-32"C. Ordinarily, optimum production is obtained after incubation periods of from about 68-180 hours, depending on whether shake-flask, stir-jar or tank fermentation is employed. When tank fermentation is to be carried out, it is desirable to produce a vegetative inoculum in a nutrient broth by inoculating the broth culture with a slant or soil culture or a lyophilized culture of the producing organism. After obtaining an active inoculum in this manner, it is transferred aseptically to the fermentation tank medium. Antibiotic production may be monitored by the paper disc-agar diffusion assay using Staphylococcus aureus 209P as the test organism.
Isolation and purification
When fermentation is complete, the BBM-1675 complex may be obtained from the broth by conventional isolation procedures, e.g. solvent extraction. Thus, for example, the whole broth may be separated by filtration or centrifugation into mycelial cake and broth supernatant. Antiobiotic in the mycelial cake may be recovered by suspending the cake in methanol, filtering off insoluble materials and concentrating the methanolic extract. Activity in the broth supernatant may be recovered by extraction with n-butanol. The above-mentioned n-butanol and methanol extracts may then be combined and evaporated azeotropicallyto an aqueous solution which deposits most of the antibiotic activity as an oily solid. The solid may then be dissolved in methanol and the solution filtered.Filtrate is concentrated and added to a mixture of ethyl acetate and water. The resulting organic extract contains the crude BBM-1675 complex which may be precipitated from solution by addition of an antisolvent such as n-hexane.
The crude BBM-1675 complex is a mixture of several components including two major bioactive components, BBM-1675 As and A2, and four minor bioactive components, BBM-1675 A3, A4, B, and B2. These bioactive components may be separated and purified by conventional chromatographic procedures. In one procedure the crude BBM-1 675 complex is first dissolved in methanol and purified by Sephadex LH-20 column chromatography using methanol as the eluting solvent. This partially purified complex may then be chromatographed on a silica gel column and eluted in a stepwise manner using chloroform plus an increasing concentration of methanol to provide BBM-1675 A1, a mixture of BBM-1675 A2, A3 and A4 and a mixture of BBM-1675 B1 and B2.The A1 component may be further purified by Sephadex LH-20 column chromatography using methanol as the eluting solvent. The mixture of A2, A3 and A4 may be separated by chromatography on a column of Bondapak C18 (Waters Associates, Inc.) using increasing concentrations of aqueous acetonitrile as the eluant. The mixture of B1 and B2 components may be separated by silica gel column chromatography using a mixture of chloroform and methanol as the eluting solvent. Further details of the preferred chromatographic separation procedures are provided in the examples which follow.
Physico-chemical properties of BBM-1675 components
The six bioactive components of BBM-1675 complex are distinguishable from each other by two TLC systems as shown in the following Table.
TABLE 4
TLC of BBM-1675 Components
Rf Values
SiO2 * Silanized
Component CHCl3-CH3OH(5; 1 vlv) CH3CN-H2O(75:25 v/v) BBM-1675A1 0.74 0.18
BBM-1675A2 0.71 0.21
BBM-1675A3 0.72 0.28 BBM-1675A4 0.71 0.78
BBM-1675 B1 0.63 0.23
BBM-1675 B2 0.60 0.16 * C18 reverse phase silica gel
Separation of BBM-1675 A2, A3 and A4 was difficult by ordinary phase TLC systems but could be achieved by a reverse phase TLC.
The individual BBM-1675 components show solubility and color reactions similar to each other. For example, they are soluble in chloroform, ethyl acetate, acetone, ethanol and methanol, slightly soluble in benzene and water, and insoluble in n-hexane and carbon tetrachloride. They give positive reactions with ferric chloride, Ehrlich and Tollen's reagents but negative responses in Sakaguchi, ninhydrin and anthrone tests.
Characteristic physico-chemical properties of BBM-1675 components are shown in Table 5 below.
TABLE 5
Physico-Chemical Properties of BBM-1675 Components BBM-1675A1 A2 A3 A4 B, B2
Melting point (dec) 156 ~158 C 147 ~ 149 C 125127'C 123 ~ 126 C 159 ~ 161 C 156 ~ 159 C (α)D27 (c 0.5, CHCl3) -191 -179A' -161" -176" -171" -122"
Anal.Found (%), C: 51.52 53.81 55.00 53.67
H: 5.81 6.31 6.52 6.35
N: 4.02 3.82 3.57 3.45 (by difference) O: 38.65 36.06 34.91 36.53 (UV Amax nm(El1Scm) in CH3OH 253 (325) 253 (281) 253 (286) 253 (257) 253 (225) 248 (212)
282(195) 282(172) 282(158) 282(153) 282(140) 279(141)
320(143) 320(128) 320(122) 320(117) 320(104) 318(103)
in 0.01 N HCl-CH3OH 253 (323) 253 (276) 253 (287) 253 (258) 253 (225) 248 (210)
282(192) 282 (167) 282(160) 282 (155) 282 (140) 279 (140)
320(144) 320 (128) 320(126) 320 (118) 320 (105) 318(103)
in 0.01 N NaOH-CH3OH 252 (325) 252 (289) 252 (280) 252 (266) 252 (236) 248 (233)
283 (172) 283 (171) 283 (162) 283 (160) 282 (141) 27 & 150) 318(1-36) 318(122) 318 (120) 318(118) 318(105) 318(110)
Mo. wt.
(approximate value) 1,300 1,100 1,100 1,400 (Gel HPLC, Finepak (GEL-101) The UV absorption maxima of BBM-1675 components were observed at 253, 282 and 320 nm, which did not shift in acidic or alkaline solution. The IR and PMR spectra of BBM-1675 A1, A2, A3 and A4 are shown in
Figures 1-4 and Figures 5-8 respectively. The 360 MHz PMR of BBM-1675 A1 indicated one acetyl (3:2.11 ppm), one N-CH3(2.52 ppm), four OCH3(3.42, 3.80, 3.88 and 3.98 ppm) and one exomethylene (4.57 and 5.48 ppm) groups, along with two aromatic (7.50 and 8.59 ppm) and one NH (11.79 ppm) protons. The CMR spectrum of BBM-1675A1 exhibited 55 carbon signals including a triple intensity signal (8:56.0 ppm, OCH3).
The molecular formula of BBM-1675A1 is deduced to be C57H72N4032 based on proton and 13C NMR spectra, micronalysis and molecular weight determination by HPLC and SIMS (secondary ion mass spectrometry).
Structural study of BBM- 1675A, Upon treatment with 0.5N HCI-CH30H at room temperature, BBM-1 675A1 loses its bioactivity and affords a lipophilic chromophore substance (compound I) along with several unidentified fragments.Compound I shows UV absorption similar to that of parent antibiotic suggesting that compound I retains the chromophoric structure of BBM-1 675A1. Two other chromophoric fragments related to compound I are obtained by alkaline hydrolysis of BBM-1 675A1: hydrolysis with 0.05N KOH-CH3OH at 55"C for one hour yields compound II having UV absorption maxima at 252,284,297 (shoulder) and 322 nm, while the reaction in 1 N KOH-CH30H affords an acidic chromophore substance designated compound Ill. Physico-chemical properties of compounds I, II and III are summarized in Table 6 below.
TABLE 6
Properties of Compounds I, Il and 111 Compound I Compound Compound lil M.p. 82 - 83"C 133" 253 - 255"C [(x]D9(c 0.2 CHCIg) -100" 0 0
Molecular formula C21H31N010 C14H17N06 C13H15NOs UV A CH30H nm (E) 244 (21,850) 252 (26,600) 248 (26,900)
max 276 (9,400) 283 (11,200) 295(14,400) 318 (6,300) 297 (sh8,800) 310 (13,500)
318 (6,300) 322(11,700)
MS m/z 457 (M+) 295 (M+) 281 (M+)
425 280 263
341 263 236
281 251 222
264 248 218
TLC (Xylene-*MEK-CH30H=5:5:1 v/v) :Rf0.58 0.66 0.13 * MEK = methyl ethyl ketone
Structural information about compounds II and lil was provided from the following spectral data and chemical transformation. The 13C and proton NMR indicated the presence of four OCH3, one =CH2, seven two > C=O and one > NH groups in compound 11. The NMR spectra of compound Ill was similar to those of II, differing only in the absence of one of the four OCH3 groups observed for compound II. This difference, together with the acidic nature of compound Ill, suggested that compound II is a methyl ester of compound
III. When heated under reflux with 1 N methanolic KOH, compound II was quantitatively converted to compound III, while compound Ill was converted to compound II by treatment with diazomethane.
Treatment of compound II with NaBH4 in C2H5OH gave a reduction product (compound IV, M+:m/z 267) which showed a -CH2OH group in the NMR in place of the -COOCH3 group of compound II. Upon hydrogenation over palladium on charcoal, compound II afforded a dihydroderivative (compound V, M+:m/z 297). The proton NMR spectrum of compound V exhibited a new doublet methyl signal and the absence of the exomethylene group present in compound II. Furthermore, one of the OCH3 groups appeared at higher field (8: 3.50 ppm) in compound V. These results indicated the presence of a
group in compound II which was reduced by hydrogenation to
group in compound V.Compound II was heated with 1 SN methanolic hydrogen chloride at 80"C for 3 hours and the hydrolyzate chromatographed on a silica gel column to afford a weakly basic compound (compound
VI, M+: m/z 211). TheIR spectrum and physico-chemical properties indicated that compound VI contained an
NH2 group. Compound VI was identified as methyl 4,5-dimethoxy-anthranilate by comparative IR and NMR studies with an authentic sample. Consequently, the structures of compounds Il-VI were determined as shown below.
Structures of compounds 11, III, IV, Vand Vl
Compound II Compound III CR //CH2 CH30 S XOCH3 - cH3 H-CC CH3 COOCH3 - \SOCH. OOH U300H NaBH4 Comound IV \ \ Compound IV - Pd/C CH3 +/MeOH 2Pd/c < H20H Compound V Compound VI . CR CH3 CH3 NH2 CR3 NH-CO-CR I OCR3 00CR CR3O 3 CH3ON 3 COOCH CH3 OOCH3 CH3 COOCH3 Upon treatment with 0.05N KOH-CH3OH at 55"C, compound I was split into a new chromophoricfragment (compound VII, CX5H21NO7, M+ : m/z 327) and a sugar (compound VIII). The NMR spectrum of VII exhibited one singlet C-CH3 and two high-field OCH3 groups in addition to three low-field OCH3 and two aromatic protons commonly observed for compounds II, V and VI. Further hydrolysis of VII with 1 SN methanolic hydrogen chloride gave compound VI which was identical with that previously obtained from II. After removal of VI, the hydrolyzate was treated with 2,4-dinitrophenylhydrazine to precipitate yellow solid which was identified as 2,4-dinitrophenylhydrazone of pyruvic acid. Thus compound VII is methyl, 4,5-dimethoxy
N-(2',2'-dimethoxypropionyl)-anthranilate. Compound Vill did not show the molecular ion peak but did show the M-OCH3 peak at m/z 131 in the mass spectrum in agreement with the molecular formula of C7H,404. The
NMR spectrum indicated 2,6-dideoxyhexopyranose structure for compound VI II. The assignment was supported by the 13C-NMR of compound I which gave rise to one C-CH3, one -CH2, three O-CH < and one anomeric carbon in addition to 15 carbon signals assignable to compound VII. The C3 proton of the sugar appeared at low-field (5: 5.39 ppm, octet) revealing the C3-OH of the sugar was esterified by the carboxyl group of VIII. The above results are summarized below:
Structures of compound 1, VII and Vlil
Compound I Compound VII Compound V:: CCa 1 OCs OC 3 Cz3a OCE3 / C330NH2 o'=83 08-/CHJOH~I\ MjOlMI-CO-t-CBj 308) 3i3 8) Co O'=83 oC ca3N OOCs3 3 C8 '=83 Ca CoC83 Ca a13 Compound VIII 08 Os C8 8 0C53 3-COCooH The molecular weight of compound 1(457) accounts for about one-third of the entire molecule of
BBM-1675A1 (proposed formula C57H72N4032; calc'd MW = 1324).The partial structure of BBM-1675 A1 is considered to be as follows:
Subsequent to the U.S. filing date of parent application Serial No. 495,231, it was discovered that components BBM-1 675 A1 and A2 described above and produced according to Example 2 below were in fact not completely pure and that certain of the characterizing properties used to define such components were inaccurate. Following additional chromatographic purification procedures as described more fully in
Examples 3 and 6 below, BBM-1675 As and A2 were isolated in more purified form and fully characterized as described below. Also, the elemental analysis data for components A3 and A4 was revised to show the presence of sulfur in these compounds and HPLC retention times were calculated for these two components.
Summarized below are the revised physico-chemical properties of the BBM-1675 components.
BBM- 1675A t Description: white to pale yellow crystals;
mp 156-158"(dec.) Elemental analysis:
Analysis 1 Analysis 2 Average
C: 51.60% C: 52.74% C: 52.17
H: 6.31% H: 5.99 H: 6.15
N: 5.31% N: 3.94% N: 4.63%
S: 8.47% S: 9.71% S: 9.09%
O (by difference):28.31% 0 (by difference): 27.62% 0 (by difference):27.96% Ultraviolet absorption spectrum:Instrument-Varian UV, Cary 219
Solvent- methanol
Concentration = 0.01356 g/l AmaxrnmJ absorptivities
320 12.4
280 sh (shoulder)
253 25.1
210 25.5
No significant change with acid or base
Optical rotation: Solvent-CHCl3 [a]D4 = -207 (C=0.0351)
A second analysis showed the following optical rotation: [α]D27 = -191" (C=0.5, CHCl3).
Infrared absorption spectrum: See Figure 9
Major absorption bands (KBr): 985,1015,1070,1110,1150,1210,1250,1308,1380,1405,1446,1520,1592,1608, 1668,1715,2920,2960,3360,3440, cm-'
Mass spectra: Instrument - VG-ZAB-2F
FAB-MS-thioglycerol
Molecular mass range ions (m/z): 1249,1357, 1463; with the addition of NaCI (m/z): 1271,1379,1485, 1597.
FAB-MS-MB (MB:matrix, m.w. 154); Molecular mass range ions (m/z): 1249, 1283, 1403, 1555; with the addition of NaCI (m/z): 1249,1271, 1303, 1425, 1483,
1577.
FAB-MS-glycerol-DMSO: Molecular mass range ions (m/z): 1215, 1247, 1279, 1293,1325,1353; with addition of NaCI (m/z): 1215,1237,1247,1269, 1325,
1347,1375.
Instrument: Kratos MS-50 FAB-MS-thioglycerol; Molecular mass range ions (m/z): 1357,1463.
Molecular weight
(based on above-described apparent MW = 1248
mass spectral data): Nuclear Magnetic Resonance Spectra: Instrument - WM360 Brucker
Solven: CDCl3
'NMR: 360 MHz8(ppm): 11.75 (1H,s); 8.55 H, s); 7.45 (1H, s); 6.61 (1H, m); 6.23(1 H, brs); 6.17 H,
brs); 5.93 (1H, d, J=9.3); 5.82(1 H, d, J=9.3); 5.7 (1H, brs); 5.49 (1H, m); 5.45 (1H, d, J=2.3); 5.38 (1H, brs); 4.95 (1H, d, J=10.2); 4.64 (2H, m); 4.54 (1H, d, J=2.3); 4.2 (1H, s); 4.15-3.35 (26-28H) [4.10 (1H, m);
4.02 (1H, brs); 3.95 (3H, s); 3.85 (3H, s), 3.79 (3H, s); 3.46 (1H, m); 3.40 (3H, s)]; 2.82-2.70 (3H, brm); 2.50 (3H, 5), 2.47 (1H, m); 2.38-2.22 (5H); 2.12 (1H, m); 2.11 (3H, 5); 1.60-1.05 (22H) [1.39 (3H, d, J=6.3); 6.31
(3H, d, J=6.3); 1.29 (3H, d, J=6.3), 1.08 (6H)]
See Figure 10
13C NMR: 90.3 MHz
See Figure 11
In a separate test the 13C NMR spectrum of purified BBM-1675 A1 was determined for a sample dissolved in
CDCI3 (80 MHz). Major peaks are indicated below.
CMR of BBM- 1675A, (80 MHz in CDCL3)
Chemical shift in ppm (Multiplicity*)
BBM-1675A1 13.7(q) 16.6(q) 17.5(q) 19.8(q) 22.2(q) 22.6(q)
23.4(q) 29.0(t) 34.0(t) 35.1 (t) 39.5(t) 47.2(d)
52.5(q) 55.6(u) 56.0(q) 57.1(d) 62.4(t) 64.5(d)
67.7(d) 68.2(d) 68.8(t) 69.2(d) 69.6(t) 70.2(d)
71.9(d) 76.0(d) 76.6(d) 77.1(u) 77.3(d) 83.4(s)
86.6(d) 88.4(s) 89.5(t) 97.2(d) 98.3(s) 99.0(d)
99.6(d) 103.8(d) 107.6(s) 112.5(d) 123.1(d) 124.9(d)
130.1(d) 131.5(s) 134.9(s) 136.7(s) 144.0(s) 147.2(s)
153.8(s) 154.4(s) 155.0(s) 160.7(s) 166.4(s) 191.8(s) *Multiplicity - q = quartet; d = doublet; u = uncertain
t = triplet; s = singlet
BBM- 1675A2
Description: white crystals; mp 147-149"C
Elemental analysis: C: 52.71% H: 5.94%
N: 3.94%
S: 9.39%
O(by difference): 28.01%
Ultraviolet absorption spectra: Instrument-Varian UV. Cary 219 Solvent: methanol
Concentration: 0.02052 g/l AmaX (nm) absorptivities
320 12.2
282 16.3
252 26.2
214 25.8
No significant change with acid or base.
Optical rotation: [D27 = - 179.4" (c 0.5, CHC13) Infrared spectra: See Figure 12
Instrument: Beckman IR Model 4240
Major absorption bands (KBr): 950,1015,1070,1100, 1155,1213,1250,1313, 1375, 1405, 1450, 1520, 1595, 1610, 1685, 1735,2940,2980,3440, cm-l.
Mass spectra: Instrument: VG-ZAB-2F
FAB-MS-thioglycerol
Molecular mass range ions (m/z): 968, 1249, 1355, 1357, 1463, 1569; with
addition of NaCI (m/z): 990, 1271,1379,1485,1593 FAB-MS-MB (MB: matrix, m.w. 154); Molecular mass range ions (m/z): 1249,
1403, 1419, 1555, 1571, 1587; with the addition of NaCI (m/z): 1249, 1271, 1425, 1441,1457,1483,1577.
FAB-MS-glycercol-DMSO; Molecular mass range ions (m/z): 1215, 1231, 1247,
1263, 1279,1293, 1309, 1325, 1326, 1341, 1353, 1369.
Molecularweight: apparent MW = 1248 (based on above-described mass spectral data)
Nuclear Magnetic: See Figure 13
Resonance Spectra
Instrument: WM 360 Bruckner
Solvent: CDCI3
'H NMR 360 MHz 3(ppm): 11.91 (1H, s); 8.62 (1H, s); 7.58 (1H, s); 6.56 (1H, m);
6.22 (1H, s); 6.15 (1H, brs); 5.91 (1H, d, J=9.6); 5.83 (1H, d, J=9.6); 5.70 H, m); 5.45 (1H, d, J=2.2); 5.44(1H, s), 5.34(1H, brs); 4.95 (1H, d, J=10.2); 4.75 (1H, m);
4.65 (1H, d, J=6.8); 4.54 (1H, d, J=2.2); 4.47 (1H, m); 4.18(1H, s); 4.10 (1H, brs), 4.05-3.50 (20-24H); [3.96 (3H, s); 3.87 (3H, s); 3.77 (3H, s)] 3.46 (1 H, m); 3.39 (3H,
s); 2.79 (1H, m); 2.73 (2H, m); 2.50 (3H, s); 2.50 (1H, m); 2.38-2.22 (3H); 2.14 (1H,
m); 2.10 (3H, s); 1.98 (2H, m); 1.65-1.45 (6-8H); 1.38 (3H, d, J=6.0); 1.34 (3H, d,
J=6.0); 1.22 (3H, d, J=6.8); 1.10 (6H).
13C NMR 90.3 MKz See Figure 14
In a separate test the 13C NMR spectrum of purified BBM-1675A2 was determined for a sample dissolved in
CDCI3 (80 MHz). Major peaks are indicated below.
BBM-1675A2 13.7 16.9 17.5 19.8 22.3 22.7 23.4 33.1
34.1 35.1 39.3 47.6 52.6 55.7 56.0 56.1
57.6 62.4 64.5 64.9 65.9 68.3 69.2 69.7
71.9 73.6 75.8 76.1 77.1 77.7 78.1 78.3
83.3 86.2 88.4 90.4 97.2 98.3 99.1 99.5
99.6 103.8 107.1 112.4 123.2 124.8 129.9 137.3
144.1 154.2 154.5 160.9 167.9 192.2
TABLE 7
Physico-chemical Properties of BBM- 1675 A3, A4, B,, B2
A3 A4 B1 B2
Melting point(dec): 125-127"C 123-126"C 159-161"C 156-159"C [α]D27(c0.5, CHCl3): -161"C -176"C -171"C -122"C
Anal.Found (%): C: 54.55 54.65
H: 6.46 6.29
N: 3.73 3.51
S: 7.49 8.07
UV AmaX nm (E11,,'m): 253 (286) 253 (257) 253 (225) 248 (212)
in MeOH 282 (158) 282 (153) 282 (140) 279 (141)
320(122) 320(117) 320(104) 318(103) in 0.01 N HCI-MeOH: 253 (287) 253 (258) 253 (225) 248 (210)
282(160) 282(155) 282(140) 279(140)
320(126) 320(118) 320(105) 318(103) in 0.01 N NaOH-MeOH: 252 (280) 252 (266) 252 (236) 248 (233)
283(162) 283(160) 283(141) 278(150)
318(120) 318(118) 318(105) 318(110)
Thin-layerchromatography (TLC) and high performance liquid chromatography {HPLC) data on BBM- 1675 components
A.Study No. 1- summary
TABLE 8
TLC and HPLC of BBM-1675 components
TLC (Rf) HPLC fretention time,
in minutes
SiO2 *Silanized Lichrosorb RP-18 CHCI3-MeOH CH3CN-H20 CH3CN-MeOH-0.1M CH3COONH4 85:1 v/v) 75:25 v/v) (5:2:3 v/v)
BBM-1675A1 0.74 0.18 13.3
BBM-1675A2 0.71 0.21 17.3
BBM-1675A3 0.72 0.28 8.0
BBM-1675A4 0.71 0.78 5.1
BBM-1675B1 0.63 0.23
BBM-1675B2 0.60 0.16 * C18 reverse phase silica gel
B. Study No.2- TLC and HPLC for purified A1 and A2 components
TLC Chromatography
Analtech GHLF Silica Gel Uniplates were used for all normal phase chromatography. Plates measuring 2.5 cm x 10 cm were used for one-dimensional TLC. These were developed in glass cylinders measuring 6.4 cm (o.d.) by 12 cm and containing 10 ml of eluant. Plates measuring 7.5 cm x 10 cm were used for two dimensional TLC.The sample was applied to the lower left hand corner 1 cm from the edges. The plate was developed first in a tank (12.7cm wide, 8.6cm deep, cm high) containing 50 ml of the first eluant. The plate was then air dried, rotated 90" counterclockwise, and developed in a second tank containing 50 ml of the second eluant.
Whatman analytical precoated C-18 silica gel plates were used for all reverse phase chromatography.
Plates measuring 2.5 cm x 7.6 cm were developed in glass cylinders measuring 10 ml of eluant.
Normal phase plates were viewed under 254 nv uv light first. The plates were then inserted into a glass cylinder (6.4 cm o.d. by 12 cm) containing 12 crystals. The plates were then reexamined after approximately 2 minutes. Reversed phase plates were visualized under 254 nm uv light only. Zones were detected by looking for quenching of the fluorescence of an impregnated dye.
Analytical HPLC
The following components were used to construct an analytical HPLC system: Waters Associates Model 6000A Solvent Delivery System pump; Varian Varichrom Model VUV-10 uv/vis Detector set at 254 nm 0.1
OD; Fisher Recordal Series 5000 Recorder; Waters Associates Model 660 Solvent Programmer; Waters
Associates Model U6K injector; Alltech, ll-Bondapak C18 (10) column (4.6 mm i.d. x 25 cm) with a Whatman
Co. Pell ODS (0.03-0.038 mm) guard column (4.6 mm i.d. x 5 cm). The components were connected with 316 stainless steel tubing (1.6 mm o.d. - 0.23 mm i.d.). Eluant was pumped at 2 ml/min for all analysis.
Preparative HPLC
The following components were used to construct a medium pressure liquid chromatography system:
Fluid Metering, Inc. Model RP-SY 2CSC FMI Lab Pump; Fluid Metering, Inc. Model PD-60LF FMI Pulse
Dampener; a 15 ml sample loop constructed of polypropylene tubing (3.0 mm o.d. x 1.5 mm i.d.) wrapped around a cardboard tube (8.65 cm o.d.); Glenco Series 3500 Universal LC columns; Instrument Specialties
Co. Model UA-5 Absorbance/Fluoresence Monitor with a Type 6 optical unit; Instrumentation Specialities Co.
Model 590 Flow Interrupter Valve; and an Instrumentation Specialties Co. Model 328 Fraction Collector. The components were connected with polypropylene and Teflon tubing (3.0 mm o.d. x 1.5 mm i.d.) and Glenco multifit connectors and valves in the order listed.
The Glenco series 3500 Universal LC Columns were slurry packed with the defined adsorbent in the designated solvent using standard techniques. The void between the settled bed and tube top was filled with standard Ottawa sand. Eluant was pumped at a maximum rate which would not exceed 60 psi back pressure (approximately 20 ml/min).
Gradient elution
A Glenco gradient elution apparatus consisting of two chambers of equal diameter, height and volume connected in tandem with a Teflon valve was used for all gradient elutions. One chamber served as a mixing chamber and one as a static reservoir. The less polar solvent was initially held in the mixing chamber. The more polar solvent was held in the static chamber. Teflon coated magnetic stirring bars (1.0 x 3.7cm) were placed in both chambers and driven by Thomas Model 15 Magne-matic stirrers. Eluant was pumped from the mixing chamber to the medium pressure HPLC system through polypropylene tubing (1.5 mm ID x 3.0 mm OD). As eluant was removed from the mixing chamber, the solvent in the static reservoir was allowed to freely replace it, thus creating a linear gradient of eluant.
TLC analysis ofBBM-1675A, andA2 Summarized in Table 9 below are the observed Rf values for BBM-1675A1 and A2 on normal phase plates.
Rf is calculated by dividing the measured distance of the center of a zone from the point of sample application by the measured distance of the solvent front from the point of sample application.
TABLE 9
Rf
SystemlCompound BBM- 1675A1 BBM- 1675A2
4% methanol in chloroform 0.33 0.30
5% methanol in diethyl ether 0.39
50% acetone in Skellysolve B 0.38 0.31
Summarized in Table 10 below are the observed Rf values of BBM-1675A1 and A2 on normal phase plates developed in two dimensions. The position of the spots are expressed in Cartesian coordinates. The X coordinate is the Rf values of the second listed solvent system. The Y coordinate is the Rf values of the first listed solvent system.
TABLE 10
Rf
SystemlCompound BBM- 1675A7 BBM- 1675A2
4% methanol in chloroform vs
5% methanol in diethyl ether (0.34, 0.33) (0.28, 0.23)
4% methanol in chloroform vs
50% acetone in Skellysolve B (0.33, 0.29)
Summarized in Table 11 below are the observed Rf values for BBM-1675A1 and A2 on C-18 reversed phase
TLC plates developed in binary eluants.
TABLE 11
Rf
SystemlCompound BBM- 1675A, BBM- 1675A2
25% 0.5 M NaCI in acetonitrile 0.18 0.21
25% water in acetonitrile 0.00 0.00
Summarized in Table 12 below are the observed Rf values of BBM-1675A1 and A2 on C-18 reversed phase
TLC plates developed with ternary eluants.
TABLE 12
Rf
SystemlCompound BBM- 1675A1 BBM- 1675A2 Acetonitrile : Methanol : 0.5 NaCL
80% : 10% : 10% 1.00 1.00
60% 10% 30% 0.57 0.50
40% 30% 30% 0.32 0.22
30% 50% 20% 0.44 0.33
50% 30% 20% 0.62 0.54
40% 40% 20% 0.60 0.49
50% 20% 20% 0.42 0.34
60% 20% 20% 0.74 0.69
Acetonitrile : Methanol : water
40% 30% : 30% 0.00 0.00
Acetonitrile : Methanol 0.1M NH40Ac 40% : 30% : 30% 0.32 0.22
Acetonitrile : Methanol : 0.1M NaH2PO4
40% : 30% : 30% 0.00 0.00
HPLC analysis of BBM- 1675A, andA2 BBM-1675A1 and BBM-1675A2 were assayed using single, binary, and ternary eluants on C-18 reversed phase silica gel columns. Summarized in Tables 13, 14 and 15 below are the observed K' values for these compounds.The K' was calculated using the following formula:
K' - TR-To
To where TR is the retension time measured from time of injection to peak apex and To is the void volume time.
TABLE 13
K'
SystemlCompound BBM- 1675A1 BBM- 1675A2
Acetonitrile a a
Tetrahydrofuran a a
Methanol 0.00 0.00 a = compound did not elutefrom column.
TABLE 14
K'
SystemlCompound BBM- 1 675A, BBM- 1 675A2 25% water in acetonitrile a a
25% methanol in water 1.25 1.25 a = compound did not elute from column.
TABLE 15
Ternary Eluants
K'
SystemlCampound BBM- 1675A, BBM- 1675A2
Acetonitrile : Methanol : water
40% 30% 30% a a
Acetonitrile : Methanol : 0.1M NH40Ac 40% : 30% : 30% 1.7 3.0
50% 20% 30% 3.8 6.5
43.3% 23.3% 33.3% 6.1 b
42.5% 22.5% 35.0% 7.8 b
41.5% 21.5% 37.0% 9.7 b a = did not elute b = not determined
Biological properties of BBM- 1675 components
Antimicrobial activity of the BBM-1675 components was determined for a variety of bacteria (grampositive, gram-negative and acid-fast) and fungi by the serial two-fold agar dilution method.Nutrient agar medium was used for gram-positive and gram-negative bacteria and No.1001 medium (3% glycerol,0.3% sodium L-glutamate, 0.2% peptone, 0.31% Na2HPO4, 0.1% KH2PO4, 0.005% ammonium citrate, 0.001% MgSO4 and 1.5% agar) for acid-fast organisms. Sabouraud agar medium was used for fungi. As shown in
Table 16, each of the six BBM-1675 components (A1, A2, A3, A4, B1, B2) showed a broad spectrum of antimicrobial activity. BBM-1 675 A1, A2, A3 and A4 in particular were highly active against gram-positive bacteria.
TABLE 16
Antimicrobial Activity of BBM-1675 Components
MIC in mcgiml Strain BBM-1675Ar A2 A3 A4 B, B2
S. aureus 209P < 0.0008 0.0063 0.0063 0.0125 0.012 0.0063
S. aureus Smith < 0.0008 0.0031 0.0063 0.0125 0.012 0.012
B. subtilis PCI 219 < 0.0008 0.05 0.0125 0.0125 0.05 0.05
M. luteus 1001 0.0016 0.0063 0.0125 0.0125 0.1 0.1
M. flavus < 0.0008 0.0016 0.0063 0.0125 0.025 0.025
Mycobacterium 607 0.05 0.1 NT NT 0.05 0.025
E. coliNIHJ 0.1 0.8 1.6 3.1 0.8 3.1
K. pneumoniae D11 0.4 0.8 1.6 3.1 0.8 0.8
P. aeruginosa D15 0.8 1.6 1.6 3.1 3.1 3.1
C. albicans IAM 4888 0.4 0.4 1.6 6.3 3.1 1.6
C. neoformans 1.6 3.1 1.6 6.3 6.3 12.5
A second antimicrobial test was carried out on purified A1 and A2 (as prepared in Ex. 3 below) and on components A3 and A4.Data is summarized below.
MIC by ADT (mcg/ml) Strain BBM-1675A, A2 A3 A4
S. aureus 209P < 0.0008 0.0063 0.0063 0.012
S. aureus Smith < 0.0008 0.0031 0.0063 0.012
B. subtilis PCI 219 < 0.0008 0.05 0.012 0.025
M. luteus 1001 0.0016 0.0063 0.012 0.05
M. flavus < 0.0008 0.0016 0.0063 0.012
Mycobacterium 607 0.05 0.1 0.16 0.16
E. coliNIHJ 0.1 0.8 1.6 3.1
K. pneumoniae D11 0.4 0.8 1.6 3.1
P. aeruginosa D15 0.8 1.6 3.1 3.1
B. fragilisA20928 0.2 1.6 0.2 0.4
C. difficileA21675 0.4 0.8 0.05 0.4
C. perfringens A9635 0.05 0.8 0.4 0.4
C. albicans lAM 4888 0.4 0.4 1.6 6.3
C. neoformans 1.6 3.1 1.6 6.3
The activity of prophage induction in lysogenic bacterium E. coliW1709 (A) was determined for BBM-1675 components according to the method of Lein et al. in Nature 196: 783-784 (1962). The plaque count was made on agar plates containing test material (T) and control plate (C). A T/C ratio of the plaque counts of greater than 3.0 was considered significant and the lysogenic induction activity (lLB activity) was expressed as the minimum inducible concentration of the test compound. As shown in Table 17, BBM-1675 components showed strong ILB activity in the lysogenic bacteria, thus suggesting that they may possess
antitumor activity.
TABLE 17
Lysogenic Induction Activity of BBM-1675 Components
Antibiotic MIC* (mcg/mI) BBM-1 675 A1 0.0063
BBM-1675 A2 0.0125
BBM-1675A3 0.05
BBM-1675 A4 0.10
BBM-1675 B1 0.10
BBM-1675 B2 0.20
* minimum inducible concentration
The antitumor activity of BBM-1675 A1 and A2 was determined in various mouse tumor systems.
Lymphocytic leukemia P-388, lymphoid leukemia L-1210, melanotic melanoma B16 and Lewis lung
carcinoma were implanted intraperitoneally into male BDF1 mice at an inoculum size of 106, 105, 5 x 105 and
106 cells per mouse, respectively. Graded doses of test compounds were administered to the mice
intraperitoneally 24 hours after the tumor inoculation. The treatments were given once on the first day only,
on day 1,4 and 7 (q3d x 3), once daily for 9 days (qd 1 < 9) or 11 days (qd 1 < 11). Components A3 and A4 were
tested only against P-388 leukemia by a q3d x 3 schedule due to short supply of material.
BBM-1675 A1, A2, A3 and A4 were dissolved in 0.9% saline containing 10% dimethyl sulfoxide, and
chromomycin A3 (Toyomycin, Takeda) employed as a reference compound was dissolved in 0.9% saline.
Death or survival of the treated and non-treated mice was recorded daily, and the median survival time
(MST) was calculated for each of the test (T) and control (C) groups. AT/C value equal to or greater than
125% indicates that a significant antitumor effect was achieved. The results are shown in Tables 18 through
23. BBM-1675 A1 and A2 showed extremely potent antitumor activity against P-388 leukemia with a
maximum T/C value of 160%. They are approximately 100 to 3000 times more active than chromomycin A3 in
terms of minimum effective dose. BBM-1675 A3 and A4, however, were less active than component A1 or A2 against P-388 leukemia (Table 19). BBM-1 675 A1 and A2 were also active against L-1 210-leukemia (Table 21), B16 melanoma (Table 22) and Lewis lung carcinoma (Table 23). The toxicity of BBM-1675 A1 and A2 was
determined in male ddY mice by intraperitoneal or intravenous administration; BBM-1675 A1 was about 10
times more toxic than BBM-1675 A2 (Table 24). The therapeutic indices of BBM-1675 A1 and A2 were 4 to 8
and 8 to 20 times better than those of chromomycin A3, respectively, in the P-388 leukemia system (Table
25). Second experiments were carried out by intravenous administration of BBM-1675 components against
P-388 and L-1210 leukemias, which were inoculated intravenously at 5 x 105 and 104 cells per mouse, respectively.In these experiments, adriamycin was used as a reference agent, which was dissolved in 0.9% saline and administered on days 1,4 and 7. The results are shown in Tables 26 and 27. Both components A1 and A2 were superior to adriamycin in terms of maximum TIC value, minimum effective dose and activity range.
TABLE 18
Effect of BBM-1675 Components on P-388 Leukemia
(Day 1 treatment) Averagewt Dose, ip MST TIC change on Survivors on {mglkgiday*) (days) (%) day 5(g) day5 day45 BBM-1675A1 0.03 19.0 152 -2.6 5/5 0/5
0.01 19.0 152 -1.0 5/5 0/5
0.003 18.0 144 -1.0 5/5 0/5
0.001 20.0 160 -1.4 5/5 0/5
0.0003 16.0 128 0.0 5/5 0/5
0.0001 15.0 120 -0.2 5/5 0/5
0.00003 14.0 112 -0.2 5/5 0/5
BBM-1675 A2 0.3 6.0 48 -3.8 3/5 0/5
0.1 20.0 160 -1.8 5/5 0/5
0.03 18.0 44 -1.4 5/5 0/5
0.01 17.0 -0.6 5/5 0/5
0.003 17.0 136 -0.4 5/5 0/5
0.001 16.0 128 0.0 5/5 0/5
0.0003 15.0 120 0.0 5/5 0/5
0.0001 14.0 112 0.0 5/5 0/5
Chromomycin A3 1 19.0 152 -0.2 4/5 0/5
0.3 17.0 136 +0.6 5/5 0/5
0.1 16.0 128 +0.8 5/5 0/5
0.03 14.0 112 0.0 5/5 0/5
0.01 14.0 112 -0.2 5/5 0/5
Vehicle - 12.5 - +0.1 10/10 0/10 * day 1, i.p.
Circle indicates a significant antitumor activity.
TABLE 19
Effect of BBM-1675 Components on P-388 Leukemia
(Days 1, 4 and 7 treatment)
Average wt.
Dose, i.p MST TIC change on Survivors on mg/kg/day*) (days)(%) day 5(g) day 5 day 45 BBM-1675A1 0.03 7.0 56 -2.8 5/5 0/5
0.01 19.0 152 -1.0 5/5 0/5
0.003 19.0 152 -0.6 5/5 0/5
0.001 16.0 (m) -0.6 5/5 0/5
0.0003 17.0 (m) -0.4 5/5 0/5
0.0001 16.0 128 -0.2 5/5 0/5
0.00003 14.0 112 +0.4 5/5 0/5 BBM-1675A2 0.3 tox. - - 2.5 0/5
0.1 11.0 88 -1.0 5/5 0/5
0.03 18.0 144 -1.2 5/5 0/5
0.01 18.0 144 -0.4 5/5 0/5
0.003 18.0 144 -0.4 5/5 0/5
0.001 17.0 136 -0.4 5/5 0/5
0.0003 16.0 128 -0.4 5/5 0/5
0.0001 16.0 128 -0.2 5/5 0/5
0.00003 15.0 120 -0.4 5/5 0/5 BBM-1675A3 0.01 17.5 62) +0.2 4/4 0/4
0.001 15.0 120 +0.6 4/4 0/4
0.0001 13.5 108 +0.6 4/4 0/4
BBM-1675A4 0.01 16.5 132 +0.2 4/4 0/4
0.001 14.0 112 +0.4 4/4 0/4
0.0001 12.5 100 +0.6 4/4 0/4
Chromomycin A3 0.3 18.0 44 +0.6 5/5 1/5 0.1 18.0 144 +0.6 5/5 0/5
0.03 17.0 136 -0.2 5/5 0/5
0.01 14.0 112 0.0 5/5 0/5
Vehicle - 12.5 - +0.4 10/10 0/10 *days1,4and7,i.p.
Circle indicates a significant antitumor activity.
TABLE 20
Effect of BBM-1675 Components on P-388 Leukemia
(qd 1- > 9 treatment)
Average wt.
Dose, ip MST TIC change on Survivors on (mg/kg/day*) (days) (%) day 5 (g) day 5 day 45
BBM-1675A1 0.01 7.0 56 -1.8 5/5 0/5
0.003 13.0 104 -1.0 5/5 0/5
0.001 19.0 152 -1.2 5/5 0/5
0.0003 19.0 152 -0.8 5/5 0/5
0.0001 18.0 144 0.0 5/5 0/5
0.00003 16.0 (m) +0.2 5/5 0/5
0.00001 16.0 -0.2 5/5 0/5
BBM-1675A2 0.1 6.0 48 -2.2 4/5 0/5
0.03 13.0 104 -1.4 5/5 0/5
0.01 18.0 144 -1.0 5/5 0/5
0.003 18.0 144 -0.6 5/5 0/5
0.001 18.0 144 -0.8 5/5 0/5
0.0003 17.0 136 -0.4 5/5 0/5
0.0001 16.0 -0.4 5/5 0/5
0.00003 15.0 120 -0.6 5/5 0/5
0.00001 15.0 120 +0.4 5/5 0/5
Chromomycin A3 0.3 9.0 72 -2.0 5/5 0/5
0.1 18.0 6 +0.4 5/5 0/5
0.03 18.0 (i) 0.0 5/5 0/5
0.01 15.0 120 -0.2 5/5 0/5
0.003 13.0 104 -0.2 5/5 0/5
Vehicle - 12.5 - +0.4 10/10 0/10 * qd 1 < 9 i.p.
Circle indicates a significant antitumor activity.
TABLE 21
Effect of BBM-1675 Components on L-1210 Leukemia
Average wt.
Dose MST TIC change on Survivors on (mglkgiday*) days (%) day 5(g) day 5 day 45 BBM-1 675 A1 0.003 14.5 153 -1.7 6/6 0/6
0.001 12.0 -0.5 6/6 1/6
0.0003 12.0 126 +0.3 6/6 0/6
0.0001 11.0 116 +1.0 6/6 0/6
BBM-1675A2 0.03 10.5 111 -1.5 6/6 0/6
0.01 13.5 142 -1.2 6/6 0/6
0.003 13.0 137 -0.2 6/6 0/6
0.001 11.0 116 +1.3 6/6 0/6
0.0003 10.5 111 +1.0 6/6 0/6
Chromomycin A3 0.3 8.5 89 -1.2 6/6 0/6
0.1 11.5 121 +1.2 6/6 0/6
0.03 11.0 116 +1.2 6/6 0/6
0.01 11.0 116 +1.3 6/6 0/6
0.003 10.0 105 +1.5 6/6 0/6
Vehicle - 9.5 - +1.4 12/12 0/12 * qd 1e0, i.p.
Circle indicates a significant antitumor activity,.
TABLE 22
Effect of BBM-1675 Components on B16 Melanoma
Average wt.
Dose MST TIC change on Survivors on
(mg/kg/day*) (days) (%) day 5 (g) day 5 day 45
BBM-1675A1 0.003 10.0 61 -0.7 6/6 0/6
0.001 31.5 191 0.0 6/6 0/6
0.0003 40.5 24 +0.3 6/6 0/6
0.0001 27.0 164 +0.8 6/6 0/6
0.00003 22.0 133 +1.8 6/6 0/6
0.00001 18.0 109 +2.2 6/6 0/6 BBM-1675A2 0.03 11.0 67 -0.8 6/6 0/6
0.01 26.5 161 +0.3 6/6 0/6
0.003 29.5 (i) +0.2 6/6 0/6
0.001 26.0 158 +0.8 6/6 0/6
0.0003 22.0 133 +0.2 6/6 0/6
0.0001 18.0 109 +0.2 6/6 0/6
0.00003 17.0 103 +1.7 6/6 0/6
Chromomycin A3 0.1 25.5 155 +2.3 6/6 0/6
0.03 23.0 139 +2.2 6/6 0/6
0.01 21.0 127 +2.3 6/6 0/6
0.003 18.0 109 +2.2 6/6 0/6
Vehicle - 16.5 - +2.1 12/12 0/12 * qd 1- > 9, i.p.
Circle indicates a significant antitumour activity.
TABLE 23
Effect of BBM-1675 Components on Lewis Lung Carcinoma Averagewt Dose MST TIC change on Survivors on {mglkgiday*) (days) (%) day 5(g) day5 day 45
BBM-1675A1 0.003 10.0 91 -1.7 5/6 0/6
0.001 31.5 286 -0.7 6/6 1/6
0.0003 21.5 195 -0.7 6/6 0/6
0.0001 21.0 191 +1.0 6/6 0/6
0.00003 13.0 118 +1.0 6/6 0/6
0.00001 11.5 105 +1.0 6/6 0/6
BBM-1675A2 0.03 10.0 91 -1.8 6/6 0/6
0.01 25.5 232 -1.7 6/6 0/6
0.003 28.5 259 0.0 6/6 1/6
0.001 17.0 155 -0.3 6/6 0/6
0.0003 15.0 136 +1.2 6/6 0/6
0.0001 10.5 95 +0.5 6/6 0/6
0.00003 11.0 100 +0.8 6/6 0/6
Chromomycin A3 0.1 21.5 195 +1.2 6/6 1/6
0.03 17.0 155 +1.7 5/5 0/5
0.01 17.0 155 +1.5 6/6 0/6
0.003 11.5 105 +1.7 6/6 0/6
Vehicle - 11.0 - +0.8 12/12 1/12 * qd 1- > 11, i.p.
Circle indicates a significant antitumor activity.
TABLE 24
Toxicity of BBM-1675 Components
LD50 fmglkgiday) Multiple dose
Single dose (qd 1 < 9) i.p i.v. i.p.
BBM-1675A1 0.019 0.010 0.00046
BBM-1675A2 0.18 0.10 0.0072
Chromomycin A3 0.81 0.41 0.23
TABLE 25
Therapeutic Indices LD501MED* P-388
Single qd 1- > 9 L1210 B16 LL BBM-1675A1 63 > 46 2 15 5
BBM-1765A2 180 72 2 24 24
Chromomycin A3 8 8 inactive 23 23 * mininum effective dose
TABLE 26
Effect of BBM- 1675 Components on Intravenously Implanted
P-388 Leukemia
Average wt.
Dose MST TIC change on Survivors on
(mg/kg/day*) (days) (%) day 5(g) day5 day 45
BBM-1675 A1 0.01 9.5 106 -1.7 6/6 0/6
0.003 14.0 156 -0.3 6/6 0/6
0.001 11.5 (m) +0.3 6/6 0/6
0.0003 9.5 100 +0.3 6/6 0/6
BBM-1675A2 0.1 7.0 78 -3.7 6/6 0/6
0.03 15.0 167 -1.0 6/6 0/6
0.01 12.0 133 -0.5 6/6 0/6
0.003 9.0 100 +1.0 6/6 0/6
Adriamycin 30 tox. - - 0/6 0/6
10 9.0 100 -1.5 6/6 0/6
3 12.0 133 +0.7 6/6 0/6
1 9.0 100 +1.7 6/6 0/6
Vehicle - 9.0 - +1.7 12/12 0/12 *days 1,4and 7, i.v.
Circle indicates a significant antitumor activity.
TABLE 27
Effect on BBM-1675 Components on Intravenously Implanted
L-1210 Leukemia
Average wt.
Dose MST TIC change on Survivors on fmglkgiday*J (days) (%) day 5(g) day 5 day 45
BBM1675A1 0.008 9.5 119 -2.0 4/6 0/6
0.004 14.0 ( -0.2 6/6 0/6
0.002 13.0 16 +0.2 6/6 0/6
0.001 9.5 119 +0.8 6/6 0/6
0.0005 9.0 113 +0.8 6/6 0/6
BBM-1675A2 0.63 11.0 138 -1.8 6/6 0/6
0.032 14.0 175 +0.2 6/6 0/6
0.16 10.5 (t) +0.8 6/6 0/6
0.008 8.0 100 +1.2 6/6 0/6
0.004 8.0 100 +0.8 6/6 0/6
Adriamycin 16 tox - 2/6 0/6
8 12.0 150 +0.2 6/6 0/6
4 9.0 113 +1.5 6/6 0/6
2 8.0 100 +1.7 6/6 0/6
Vehicle - 8.0 - +1.4 12/12 0/12 *days 1,4and7, i.v.
Circle indicates a significant antitumor activity.
Antitumor activity of components BBM-1675 A1 and A2 was also determined by a second test against P-388 leukemia, L-1210 leukemia and B16 melanoma in mice. Results of these tests are shown below in Tables 28, 29 and 30. Details of the methods used in these tests have been described in Cancer Chemother. Rep. 3: 1-87 (Part 3), 1972.
TABLE 28
Effect of BBM-1675 A7 and A2 on P-388 Leukemia
Effect A WC,
Treatment Dose, IP MST MST gm Survivors
Material Schedule Fglkgiday Days % TIC d.5 d.5(30) * NSC38270 qd 1 < 9 400 13.0 163 -0.6 6/6
200 11.0 138 -0.9 6/6
BBM-1675A1 d.1 51.2 20.0 250 -2.1 4/6 DMSO~saline 25.6 18.0 225 -1.8 6/6
12.8 16.5 206 -1.1 6/6
6.4 13.0 163 +0.1 6/6
3.2 12.0 150 -0.3 6/6
1.6 11.0 138 -0.3 6/6
0.8 10.5 131 0 6/6
0.4 10.0 125 +0.4 6/6
0.2 10.0 125 +0.3 6/6
0.1 10.0 125 0 6/6 d.1,5 & 25.6 8.0 100 -1.8 6/6
12.8 13.5 169 -1.5 6/6
6.4 16.5 206 -0.8 6/6
3.2 16.0 200 -0.8 6/6
1.6 15.5 194 +0.3 6/6
0.8 12.5 156 +0.3 6/6
0.4 12.0 150 -0.1 6/6
0.2 11.5 144 +0.2 6/6
0.1 12.0 150 +0.8 6/6
0.05 10.0 125 +0.8 6/6 qd1 < 9 12.8 TOX TOX TOX 1/6
6.4 6.0 75 -1.5 4/6
3.2 13.0 163 -1.2 6/6
1.6 14.5 181 -1.6 6/6
0.8 16.5 206 -2.3 6/6
0.4 16.0 200 -0.9 6/6
0.2 15.0 188 -0.8 5/5
0.1 13.0 163 -0.4 6/6
0.05 12.0 150 +0.1 6/6
0.025 12.0 150 -0.7 6/6
BBM-1675A2 d.1 256 TOX TOX TOX 0/6 DMSOesaline - 128 12.5 156 -3.5 4/6
64 27.0 338 -1.9 6/6
32 26.0 325 -2.0 6/6
16 16.0 200 -1.8 6/6
8 15.5 194 -1.9 6/6
4 15.0 188 -0.7 6/6
2 12.0 150 -0.5 6/6
1 12.0 150 0 6/6
0.5 10.0 125 +0.2 6/6 d.1,5 & 128 TOX TOX TOX 0/6
64 TOX TOX TOX 0/6
32 TOX TOX -1.3 2/6
16 24.5 306 -1.3 5/5
8 17.5 219 -1.1 6/6
4 15.0 188 0 6/6
2 15.0 188 +0.1 6/6
1 12.5 156 -0.4 6/6
0.5 12.0 150 -0.4 6/6
TABLE 28 - cont'd
BBM-1675 A2 DMSOesaline 0.25 11.0 138 -0.4 6/6 qd1 < 9 64 TOX TOX TOX 1/6
32 6.0 75 -2.9 4/6
16 8.0 100 -1.9 6/6
8 15.5 194 -1.3 6/6
4 17.0 213 -1.8 6/6
2 15.0 188 -1.1 6/6
1 14.0 175 -0.5 6/6
0.5 14.0 175 -0.6 6/6
0.25 12.0 150 -0.1 6/6
0.125 12.0 150 +0.1 6/6
Control Saline 8.0 - +0.5 10/10
Tumor inoculum 106 ascites cells implanted i.p.
Host : CDF1 9 mice.
Tox . < 4/6 mice alive on d.5
Evaluation : MST = median survival time.
Effect : %T/C = (MSTtreated/MSTcontrol) x 100.
Criteria : % T/C 2 125 considered significant antitumor activity.
* NSC 38270 = olivomycin A
TABLE 29
Effect on BBM-1675 A1 and A2 on L-1210 Leukemia
Effect A WC,
Treatment Dose, IP MST MST gm Survivors on
Material Schedule Aglkglinj Days % TIC d.5 d.5(30)
BBM-1675A1 d.1 51.2 12.0 171 -1.1 5/6
25.6 7.0 100 -2.3 6/6
12.8 9.0 129 -1.1 5/6
6.4 9.5 136 -0.5 6/6
3.2 6.0 86 -1.7 6/6
1.6 7.0 100 -0.8 6/6
0.8 8.0 114 -0.4 6/6
0.4 7.0 100 +0.3 6/6
0.2 7.0 100 -0.5 5/6
0.1 7.0 100 +0.8 5/6
d.1,5 & 25.6 TOX TOX TOX 1/6
12.8 9.0 129 -1.8 6/6
6.4 9.0 129 -0.8 6/6
3.2 8.0 114 -1.9 6/6
1.6 8.5 121 ' 0 6/6
0.8 8.0 114 -0.4 6/6
0.4 7.5 107 -1.3 6/6
0.2 8.0 114 0 6/6
0.1 8.0 114 +0.4 5/6
0.05 7.0 100 +0.3 6/6
qd 1 < 9 12.8 TOX TOX -2.4 3/6
6.4 8.0 114 -1.6 6/6
3.2 8.0 114 -1.7 6/6
1.6 9.0 129 -2.1 6/6
0.8 8.5 121 -1.6 6/6
0.4 8.0 114 -1.0 6/6
0.2 8.0 114 -0.5 5/6
0.1 7.0 100 +0.3 6/6
0.5 7.0 100 +0.3 6/6
0.025 6.0 86 -0.6 6/6
BBM-1675A2 d.1 256 TOX TOX TOX 0/6
128 7.0 100 -1.8 5/6
64 7.5 107 -1.3 4/6
32 8.0 114 -2.2 5/6
16 7.0 100 -2.3 6/6
8 9.5 136 -1.4 6/6
4 8.5 121 -1.1 6/6
2 8.0 114 -0.8 6/6
1 8.0 114 0 6/6
0.5 8.0 114 -0.1 6/6
TABLE 30
Effect of BBM-1675 At and A2 on B16 Melanoma
Effect A WC
Dose, IP MST MST gm Survivors on
Material g (m) or mg/kg/inj Days % TIC d.5 d. 10(61) BBM-1675A1 3.2M TOX TOX -1.8 2/10
1.6 16.0 168 -1.8 10/10
0.8 34.5 168 -1.8 10/10
0.4 56.5 226 -0.9 10/10(2)b
0.2 47.0 188 -0.7 10/10
0.1 37.0 148 -0.4 10/10 BBM-1675A2 16M 13.0 52 -2.1 10/10
8 29.5 118 -2.0 10/10
4 43.5 174 -1.1 10/10
2 50.5 202 -2.1 10/10(3)b
1 0.5 140 -1.0 10/10
0.5 38.0 152 -1.1 10/10
Control Saline 25.0 - -0.1 10/10
a Only one without tumor; MST d.m.o. = 55.0 (220%), b Two without tumor; MST d.m.o. = 46.0 (184%) Tumor inoculum : 0.5 ml of a 10% brei, p
Host : BDF1 ? mice.
Treatment : qd 1- > 9
Tox : #7/10 mice alive on d.10
Evaluation : MST = median survival time
Effect : %T/C = (MSTtreated/MSTcontrol) x 100.
Criteria : nC 2 125 considered significant antitumor activity.
After further purification of BBM-1675A1 according to ExampleS, samples of the purified compound were tested against L-1210 leukemia, P-388 leukemia and B16 melanoma in mice. Results of these tests are shown below.
TABLE 31
Effect of Purified BBM-1675At on P388 Leukemia
(Day 1 Treatment)
Average vvt.
Dose MST TIC change on Survivors on
Compound (mglkgldosel Route, schedule Days (O/oJ day5 day5
BBM-1675A1 0.1024 i.p., qd x 1 TOX TOX 0/6
0.0512 17.5 159 -1.8 4/6
0.0256 16.5 150 -2.6 6/6
0.0128 17.5 159 -1.4 6/6
0.0064 15.5 141 -2.2 6/6
0.0032 15.5 141 -2.5 6/6
0.0016 16.5 150 -1.0 6/6
0.0008 15.0 136 -1.2 6/6
0.0004 15.0 136 -2.6 6/6
0.0256 i.p., q4d x 3; TOX TOX -1.5 1/6
0.0128 10.0 91 -2.5 5/6
0.0064 17.5 159 -1.9 6/6
0.0032 17.0 155 -0.8 6/6
0.0016 17.0 155 -2.0 6/6
0.0008 15.0 136 -1.7 6/6
0.0004 15.0 136 -0.4 6/6
0.0002 13.0 118 -0.8 6/6
0.0001 13.0 118 -1.3 6/6
0.00005 13.5 123 -1.0 6/6
0.0128 i.p., qd x 5;TOX TOX 0/6
0.0064 TOX TOX -3.6 3/6
0.0032 17.5 155 -2.2 5/6
0.0016 14.5 132 -2.0 6/6
0.0008 15.5 141 -2.2 6/6
0.0004 16.0 145 -2.8 6/6
0.0002 17.0 155 -1.3 6/6
0.0001 14.0 127 -1.6 5/6
0.00005 15.0 136 -1.6 6/6
0.000025 15.0 136 -1.0 6/6
Control
(vehicle) 1 x 10e i.p., q4d x 3; 11.0 100 -0.7 9/9
Host: CDF1 female mice
Implant level and site: 1 x 106 cells, i.p.
TABLE 32
Effect of Purified BBM-1675At on L-1210 Luekemia
(Day 1 Treatment)
Average wt.
Dose MST TIC change on Survivors on
Compound {mglkgidose) Route, schedule Days (O/o) day 5 day 5
BBM-1675A1 0.1024 i.p., qd x 1 TOX TOX 1/6
0.0512 TOX TOX -2.0 0/6
0.0256 8.0 114 -2.9 4/6
0.0128 11.0 157 -2.0 6/6
0.0064 11.0 157 -1.9 6/6
0.0032 10.0 143 -2.0 6/6
0.0016 10.0 143 -2.6 5/6
0.0008 8.0 114 -0.4 6/6
0.0256 i.p., q4d x 3 TOX TOX -2.3 2/6
0.0128 10.5 150 -1.7 6/6
0.0064 11.0 157 -1.8 6/6
0.0032 11.0 157 -1.4 6/6
0.0016 10.5 150 -1.9 6/6
0.0008 9.0 129 -0.6 6/6
0.0004 8.5 121 -0.7 6/6
0.0002 8.0 114 -0.5 6/6
0.0128 i.p., qd x 5 TOX TOX -2.8 2/6
0.0064 7.0 100 -1.8 5/6
0.0032 11.5 164 -1.0 6/6
0.0016 11.0 157 -1.5 6/6
0.0008 10.0 143 -1.6 5/6
0.0004 8.5 121 -0.4 6/6
0.0002 8.5 121 0.1 6/6
0.0001 8.5 121 0.0 6/6
Control
(vehicle) 1 x 106 i.p., qd x 5 7.0 100 0.1 10/10
Host: CDF1 female mice
Implant level and site: 1 x 106 cells, i.p.
TABLE 33
Effect of Purified BBM-1675A1 on B16 Melanoma
(Day 1 Treatment)
Average wt.
Dose MST TIC change on Survivors on
Compound (mglkgldoseJ Route, schedule Days 1%1 day5 day5
*BBM-1675A1 0.0064 i.p., q4d x 3 16.5 110 -3.8 8/10
0.0032 22.5 150 -3.0 10/10
0.0016 25.0 167 -1.8 10/10
0.0008 22.0 147 -2.3 10/10
0.0004 24.0 160 -1.8 9/10
0.0016 i.p., qd x 9 27.0 180 -3.7 10/10
0.0008 27.0 180 -2.9 10/10
0.0004 26.0 173 -2.3 10/10
0.0002 24.5 163 -2.4 10/10
0.0001 25.5 170 -2.3 10/10
Control
(vehicle) 0.5 ML i.p., qd x 9 15.0 100 -0.3 10/10
**BM-1675A1 0.0064 i.v., q4d x 3 15.0 86 -4.7 10/10
0.0032 32.5 186 -2.1 10/10
0.0016 26.0 149 -1.4 10/10
0.0008 24.0 137 -0.4 10/10
0.0004 24.5 140 -0.0 10/10
0.0064 i.p., q4d x 3 18.0 103 -2.7 10/10
0.0032 23.0 131 -1.4 10/10
0.0016 24.0 137 -0.7 10/10
0.0008 25.5 146 -0.8 10/10
0.0004 21.5 123 -1.4 10/10
Control
(vehicle) 0.2 ML i.v., q4d x 3 17.5 100 -0.4 10/10
Host: BDF1 female mice
*Implant level and site: 0.5ML 10% BREI, i.p.
**Implant level and site: Fragment, s.c.
The above screening data indicates that the purified BBM-1675A1 component has substantially the same antitumor properties as the less purified sample screened previously. The compound has exceptionally high potency since activity has been demonstrated at a dose of 25 nanograms/kg on a daily times 5 schedule against P-388 leukemia in mice. On tests against P-388 and L-1210 leukemias, BBM-1675A1 is effective whether given as a single injection, day 1, every fourth day for 3 injections, or daily times 5. Against B16 melanoma the compound was equally effective given intravenously to animals bearing subcutaneous tumors as when it was given intraperitoneally to animals bearing ip tumor implants. This property of successful pharmacologic delivery of a drug to a tumor at a distant site is unusual among antitumor antibiotics.
As shown above the BBM-1675 components possess potent antimicrobial activity and are thus useful in the therapeutic treatment of mammals and other animals for infectious diseases caused by such microorganisms. Additionally the components may be utilized for other conventional applications of antimicrobial agents such as disinfecting medical and dental equipment.
The induction of prophage in lysogenic bacteria and the activity shown against mouse tumor systems indicate that the BBM-1675 components are also therapeutically useful in inhibiting the growth of mammalian tumors.
The present invention, therefore, provides a method for therapeutically treating an animal host affected by a microbial infection or by a malignant tumor which comprises administering to said host an effective antimicrobial ortumor-inhibiting dose of BBM-1675 A1, A2, A3, A4, Bi or B2, or a pharmaceutical composition thereof.
In another aspect, the present invention provides a pharmaceutical composition which comprises an effective antimicrobial or tumor-inhibiting amount of BBM-1675 A1, A2, A3, A4, B1 or B2 in combination with an inert pharmaceutically acceptable carrier or diluent. These compositions may be made up in any pharmaceutical form appropriate for parenteral administration.
Preparations according to the invention for parenteral administration include sterile aqueous or non-aqueous solutions, suspensions or emulsions. They may also be manufactured in the form of sterile solid compositions which can be dissolved in sterile water, physiological saline or some other sterile injectable medium immediately before use.
It will be appreciated that the actual preferred amounts of the BBM-1675 antibiotics used will vary according to the particular component, the particular composition formulated, the mode of application and the particular situs, host and disease being treated. Many factors that modify the action of the drug will be taken into account by those skilled in the art, for example, age, body weight, sex, diet, time of administration, route of administration, rate of excretion, condition of the host, drug combinations, reaction sensitivities and severity of the disease. Administration can be carried out continuously or periodically within the maximum tolerated dose. Optimal application rates for a given set of conditions can be ascertained by those skilled in the art using conventional dosage determination tests in view of the above guidelines.
The following examples are provided for illustrative purposes only and are not intended to limit the scope of the invention.
Example 1
Fermentation of BBM- 1675
Actinomadura strain No. H964-92 was grown and maintained on an agar slant containing 1% malt extract, 0.4% glucose, 0.4% yeast extract, 0.05% CaCO3 and 1.6% agar. A well-grown agar slant was used to inoculate vegetative medium containing 3% soluble starch, 3% dry yeast, 0.3% K2HPO4, 0.1% KH2PO4, 0.05% MgSO4-7H2O,0.2% NaCI and 0.1% CaCO3, the pH being adjusted to pH 7.0 before sterilization.The vegetative culture was incubated at 32"C for 72 hours on a rotary shaker (250 rpm) and 5 ml of the growth was transferred into a 500-ml Erlenmeyer flask which contained 100 ml of fermentation medium composed of 3% cane molasses, 1% corn starch, 1% fish meal, 0.1% CaCO3 and 0.005%CuSO4-5H2O (pH 7.0 before sterilization). The fermentation was carried out at 28"C for six days on the rotary shaker. The antibiotic activity in the fermentation broth was determined by the paper-disc agar diffusion using Staphylococcus aureus 209P as the test organism. The antibiotic potency reached a maximum of about 1 mcg/ml after five days fermentation.
Fermentation of BBM-1675 was also performed in stir-jar fermenters. Five hundred mililiters of inoculum growth as prepared above was transferred into 20-liter jar fermenters containing 10 liters of fermentation medium which consisted of the same ingredients as used in the shake flask fermentation. The fermentation was carried out at 320C with an aeration rate of 12 liters/minute and agitation at 250 rpm. Under these conditions, the antibiotic production reached a maximum of about 0.9 mcg/ml after 68-76 hours of fermentation.
Fermentation studies were also carried out in fermentation tanks. A seed culture was shaken for four days at 30"C in Erlenmeyer flasks containing vegetative medium consisting of 3% soluble starch, 3% dry yeast, 0.3% K2HPO4, 0.1% KH2PO4, 0.05% MgSO47H2O, 0.2% NaCI and 0.1% CaCO3. The seed culture was inoculated to a 200-liter seed tank containing 130 liters of seed medium having the same composition as above, and the seed tank was stirred at 240 rpm at 30"C for 31 hours. The second seed culture was used to inoculate 3,000 liters of fermentation medium containing 1 % corn starch, 3% cane molasses, 1% fish meal, 0.005% CuSO4-5H2O and 0.1% CaCO3.The production tank was operated at 28"C at 164 rpm with an aeration rate of 2,000 liters/minute. The broth pH gradually rose with the progress of fermentation and reached 7.7-7.8 after 170-180 hours, when a peak antibiotic activity of 1.7 mcg/ml was produced.
Example 2
Isolation and purification of BBM- 1675 components
The harvested fermentation broth (3,000 liters, pH 7.8) was separated to mycelial cake and supernate with the aid of a Sharpless centrifuge. The mycelial cake was suspended in 1,600 liters of methanol and the mixture stirred for one hour. The insoluble materials were filtered off and the methanolic extract was concentrated in vacuo to 43 liters. The activity contained in the broth supernate was recovered therefrom by extraction with two 1,000-liter portions of n-butanol. The n-butanol extracts and concentrated methanol extracts were combined and evaporated azeotropically by occasional additions of water to an aqueous solution (20 liters) which deposited most the antibiotic activity as an oily solid. The solid was digested in 30 liters of methanol and the insolubles were removed by filtration.The methanol extract was then concentrated in vacuo to a 10-liter solution, to which was added 40 liters of ethyl acetate and 30 liters of water. After being stirred for 30 minutes, the organic layer was separated, dried over sodium sulfate and evaporated in vacuo to 4 liters. Addition of the concentrate into 20 liters of n-hexane afforded a pale yellow solid of crude BBM-1675 complex (90.14 g, potency: 55 mcg/mg). The complex was shown in TLC to be a mixture of two major components, BBM-1675 A1 and A2, and several minor ones. They were separated and purified by repeated chromatographies which were performed in a cooled room to prevent deterioration.
The BBM-1675 complex (20 g) was dissolved in methanol (20 ml) and charged on a column of Sephadex
LH-20 ( 5.5 x 85 cm). The column was developed with methanol and the elution monitored by bioassay using Staphylococcus aureus 209P. The active eluates were combined, concentrated in vacuo and lyophilized to give a semi-pure solid of BBM-1675 complex (4.19 g). The solid was then chromatographed on a column of silica gel (p5 5.0 x 50 cm) using chloroform plus an interesting amount (15%vN) of methanol as eluants.
Eluates were pooled on the basis of antibacterial activity (vs. S. aureus) and TLC (SiO2; CHCl3-CH3OH = 5:1 v/v and concentrated in vacuo. Nearly homogeneous BBM-1675 A1 (yield after evaporation: 351 mg) was eluted first with 2% methanol in chloroform and then a mixture of BBM-1 675 A2, A3 and A4 (507 mg) followed by BBM-1675 B mixture (210 mg) with 3% methanol in chloroform. The solid of BBM-1675 A1 was applied on a column of Sephadex LH-20 ( 2;0 x 80 cm) which was developed with methanol. The active fractions were concentrated in vacuo to dryness and the residual solid was crystallized from methanol to afford colorless .plates of pure BBM-1675 A1 (124 mg) (this material is starting material for Example 3A.).The compled
BBM-1675 A2, A3 and A4 was separated by chromatography on a column of Bondapak C18 (Waters, Z 3.0 x 50 cm). Elution was carried out with aqueous acetonitrile-and the bioactive eluates were examined by TLC (Merck, *Silanized: CH3CN-H2O = 75:25 v/v). The minor components A4 (33 mg) and A3 (18 mg) were eluted successively in that order with 20% acetonitrile followed by another major component A2 (301 mg) (this material is starting material for Example 3B) with 50% acetonitrile).
The solid containing BBM-1675 B1 and B2 was chromatographed on a column of silica gel ( 3.0 x 40 cm) with chloroform and methanol as the developing solvent. The active fractions eluted with 4% methanol in
chloroform were combined and evaporated to afford pure BBM-1675 B1 (7 mg). Another active fraction was
eluted at 5% methanol concentration, which upon evaporation afforded BBM-1675 B2 (8 mg).
*C18 reverse phase silica gel
Example 3
Further purification of BBM- 1675A 1 and A2 A. Purification of BBM- 1675A, A2.67 cm i.d. x 75 cm Glenco column was slurry packed with Baker bonded phase octadecyl (C18) silica gel (40 micron particle size) in methanol. The column was connected into a medium pressure HPLC system and equilibrated with 1.5 1 of eluant (41.6% acetonitrile - 21.6% methanol - 36.8% 0.1 M ammonium acetate).
Partially purified BBM-1675A1 (100.5 mg) obtained according to the purification procedure of Example 2 was dissolved in 2 ml of acetonitrile and drawn into the sample loop. The sample was pumped onto the column.
The column was eluted with the above eluant collecting 87 ml fractions. The eluant was monitored at 254 nm and 340 nm. Fractions 55 through 71 were pooled and extracted twice with 1500 ml aliquots of chloroform.
The chloroform was evaporated to dryness to yield 89.8 mg of residue C.
A 1.5 cm i.d. x 20 cm Glenco column was slurry packed with 12 g of Woelm silica gel (60-200 micron particles). Residue C was applied to the column in a chloroform solution. The column was eluted with a 500 ml linear gradient of chloroform to 10% methanol in chloroform collecting 20-25 ml fractions. After analysis by TLC on silica gel, fractions 6-9 were pooled and evaporated to dryness to yield 73 mg of residue D.
A 1.5 cm i.d. x 20 cm Glenco column was slurry packed with 12 g Woelm silica gel (63-200 micron particles) in Skellysolve B. Residue D was dissolved in approximately 2 ml of CHCl3 and applied to the column. The chloroform was displaced with 25 ml of Skellysolve B. The column was then eluted with a 500 ml linear gradient of Skellysolve B to 60% acetone in Skellysolve B collecting 28-25 ml fractions. Fractions 19-23 were pooled and evaporated to dryness to yield 65.6 mg of pure BBM-1 675A1.
This residue was homogeneous in three TLC systems (5% methanol in chloroform; 5% methanol in ether; and 50% acetone in Skellysolve B on silica gel) and HPLC (C-18 silica gel -41.5% acetonitrile:21 .5% methanol:37.0%0.1 M ammonium acetate).
Gel permeation chromatography with purified BBM- 1675A, A 2.5 cm i.d. x 45 cm Pharmacia column was slurry packed with Sephadex LH-20 in methanol and adjusted to a 33.4 cm chromatography bed. Purified BBM-1675A1 (approximately 120 mg) was dissolved in 2 ml of methanol and transferred to a 2.5 ml sample reservoir. The sample was applied to the column and elution commenced at 1.75 ml/min with methanol collecting 10 ml fractions [Pharmacia Frac-100 fraction collector].
The eluant was monitored at 254 nm with an Isco UA-5 detector. BBM-1675A1 was observed to elute at VeNt of 0.79 to 0.91 (Ve= elution volume; Vt= bed volume).
B. Purification ofBBM-1675A2 A 2.65 cm i.d. x 75 cm Glenco column was slurry packed with Baker bonded phase octadecyl (C18) silica gel (40 micron particle size) in methanol. The column was connected into the medium pressure HPLC system and equilibrated with 1.51 of eluant (50% acetonitrile - 20% methanol - 30% 0.1 M ammonium acetate).
Partially purified BBM-1675A2 (76.9 mg) as obtained by the procedure of Example 2 was dissolved in 2 ml of acetonitrile and drawn into the sample loop. The sample was pumped onto the column. The column was eluted with the above eluant collecting 87 ml fractions. The eluant was monitored at 254 and 340 nm.
Fractions 31 through 38 were pooled and extracted twice with 500 ml aliquots of chloroform. The chloroform was evaporated to dryness to yield 65.8 mg of homogeneous BBM-1675A2.
BBM-1675A2 was homogeneous in 2 TLC systems, one 2-d TLC analysis and HPLC.
Example 4
Prefered extraction process for BBM- 1675A t Raw fermentation (6.8 1) obtained according to the general procedure of Example 1 was transferred to a
polypropylene bucket (12 cm d, top; 10 cm d, bottom; 37 cm high) equipped with a faucet at the bottom. An
equal volume of chloroform was added. The mixture was stirred at a good rate with a CRC-air driven stirrer for 2 hours. Approximately 41(1.3 kg) of Dicalite (filter aid) was added and allowed to mix in. The mixture
was filtered on a Dicalite pad which was held in a No. 12 Buchnerfunnel. The filtrate was collected in a 19 1 solution bottle equipped with a vacuum take-off (Ace. No. 5396-06). The mat was washed with 2 liters of
chloroform.The filtrate was transferred to a 20 1 separatory funnel and the phases allowed to separate. The
lower phase (chloroform) was removed.
A 2.5 cm i.d. x 40 cm Glenco tube was slurry packed with 91 g of Woelm silica gel (63-200 micron
particles). Using an FMI RPY-2CSD pump, the above chloroform phase was pumped through the column.
The column was rinsed with 600 ml of fresh chloroform. The chloroform eluant was discarded. The column was then eluted with 600 ml of 10% methanol in chloroform. This eluant was evaporated to dryness to yield
547 mg of residue A.
Residue A was dissolved into 50 ml of chloroform. The chloroform solution was added to 20 g of Dicalite in
a 11 round bottom flask. A slurry was created by adding approximately 200 ml of Skellysolve B. The solvents
were moved in a rotary evaporator. The residue was slurried in 300 ml of Skellysolve B. The slurry was
packed into an Ace flask chromatography tube (Part No. B5872-14) (41 mm id x 45.7 cm) by the following
procedure. A glass wool plug was inserted into the throat of the stop cock between the cock and the column tube. A 1 cm layer of standard Ottawa sand was added above the glass wool. The stopcock, glass wool and
sand bed were purged of air by passing a pressurized (5.7 psi) flow of Skellysolve B through them. The slurry was then added to the column and allowed to form a packed bed under pressurized flow. The column was
never allowed to go dry.After a stable column bed was obtained, a 2 cm layer of Ottawa sand was added
onto the top of the bed. The bed was then eluted with an additional 600-700 ml of Skellysolve B. The bed was
eluted with 500 ml of toluene. The toluene eluant was evaporated to dryness to yield 93 mg of residue B. This
partially purified BBM-1 675A1 may then be further purified according to the procedure of Example 3.
Example 5
Fermentation of BBM- 1675 complex using variant H964-92-A 1327Y A variant strain Al 327Y, which was obtained by NTG treatment of Actinomadura verrucosospora strain
No. H964-92, was used to inoculate vegetative medium containing 2% soluble starch, 1% glucose, 0.5% yeast extract, 0.5% NB-amine type A and 0.1% CaCO3, the pH being adjusted to 7.0 before sterilization.The vegetative culture was incubated at 32"C for four days on a rotary shaker (250 rpm) and 5 ml of the growth was transferred into a 500 ml Erlenmeyer flask which contained 100 ml of fermentation medium composed of 3% cane molasses, 1% corn starch, 1% fish meal, 0.005% CuSO45H20, 0.05% MgSO4.7H20 and 0.1% CaCO3, the pH being adjusted to 7.0 before sterilization.
The fermentation was carried out at 280C for 7 days on the rotary shaker. The antibiotic production reached a maximum of ca. 1.5 mcg/ml.
Example 6
Isolation and purification of BBM- 1675 components
The harvested fermentation broth from Ex. 5 (3,000 L, pH 7.6) was separated to mycelial cake and supernate by using a Sharpless centrifuge. The mycelial cake was stirred with 2,000 L of methanol for one hour and the insoluble materials were removed by filtration. The activity contained in the broth supernate was extracted therefrom with 1,800 L of n-butanol. The methanol and n-butanol extracts were combined and concentrated azeotropically by occasional additions of water to an aqueous solution (20 L) which deposited most of the antibiotic activity as an oily solid. The mixture was shaken-three times with 20 Leach of ethyl acetate to extract the activity. The extracts were pooled, filtered to remove the insolubles and evaporated in vacuo to 4 L.Addition of the concentrate into 30 L of n-hexane under stirring afforded pale yellow solid of crude BBM-1675 complex (81.7 g, potency: 59 mcg/mg). The complex was shown by TLC and HPLC to be a mixture of two major components, BBM-1675 A1 and A2 and several minor ones. They were separated and purified by a series of chromatographies which were carried out in a cold room to prevent deterioration.
The crude BBM-1675 complex (20 g) was dissolved in methanol (20 ml) and charged on a column of
Sephadex LH-20 (a 5.5 x 85 cm). The column was developed with methanol and the elution monitored by bioassay using Staphylococcus aureus 209P. The active eluates were pooled, concentrated in vacuo and lyophilized to give a semi-pure solid of BBM-1675 complex (4.86 g, potency: 203 mcg/mg). The solid was then chromatographed on a column of silica gel ( 3.0 x 70 cm) using chloroform and an increasing amount (1-5%) of methanol as developing solvents. The eluates were pooled on the basis of antibacterial activity against S. aureus and TLC (SiO2, CHC13-MeOH = 5:1, v/v) and concentrated in vacuo. BBM-1675 An (425 mg after evaporation, potency: 960 mcg/mg) was eluted first with 2% methanol in chloroform and then a mixture of BBM-1675 A2, A3, and A4 (732 mg, potency: 340 mcg/mg) followed by BBM-1675 B complex (200 mg, potency: 190 mcg/mg) with 3% methanol in chloroform. The above BBM-1675 A1 was rechromatographed on silica gel (column: a 2.2 x 44 cm) with 2% methanol in benzene. The bioactive eluates were examined by
HPLC (Lichrosorb RP-18: CH3CN-MeOH-0.1 MCH3COONH4 = 5:2:3, v/v) and the fractions containing homogeneous BBM-1 675 A1 evaporated in vacuo to dryness. The residual solid was crystallized from methanol (10 ml) to give colorless prisms of BBM-1675 A1 (197 mg, potency: 1,000 mcg/mg).
The complex of BBM-1675 A2, A3 and.A4 (537 mg) was separated by column chromatography on Bondapak
C18 (Waters, a 2.0 x 42 cm). Elution was carried out with aqueous acetonitrile and the bioactive eluates were examined by TLC (Merck, silanized: CH3CN-H2O = 75:25, v/v). The minor components BBM-1675 A4 (45 mg, potency: 410 mcg/mg) and A3 (19 mg, potency: 300 mcg/mg) were eluted successively with 20% acetonitrile followed by a major component, BBM-1675 A2 (203 mg) with 50% acetonitrile. The BBM-1675 A2 fraction was crystallized from chloroform-n-hexane to deposit colorless rods (70 mg, potency: 290 mcg/mg). The solid containing BBM-1675 B mixture was chromatographed on a column of silica gel (a 3.0 x 40 cm) with chloroform and methanol as developing solvent The active fractions eluted with 4% methanol in chloroform were pooled and evaporated to afford pure BBM-1675 B1 (7 mg, potency: 180 mcg/mg). Another active fraction was eluted at 5% methanol concentration, which upon evaporation afforded BBM-1675 B2 (8 mg, potency: 140 mcg/mg).
Claims (36)
1. The antitumor antibiotic BBM-1 675 A1 which in substantially purified form:
(a) appears as white to pale yellow crystals;
(b) is soluble in chloroform, ethyl acetate, acetone, ethanol and methanol, slightly soluble in benzene and water, and insoluble in n-hexane and carbon tetrachloride;
(c) gives a positive reaction with ferric chloride, Ehrlich and Tollen's reagents and a negative reaction in
Sakaguchi, ninhydrin and anthrone tests;
(d) exhibits an infrared absorption spectrum (KBr) substantially as shown in Figure 9;
(e) when dissolved in CDC13 exhibits a proton magnetic resonance spectrum substantially as shown in
Figure 10;
(f) has a melting point in the range of about 156-158"C;; (g) has an optical rotation of [o],,27 = -191" (e 0.5, CHC13); (h) has an apparent molecular weight of 1248 as determined by mass spectroscopy;
(i) has an approximate elemental composition of 52.17% carbon, 6.15% hydrogen, 4.63% nitrogen, 9.09% sulfur and 27.96% (by difference) oxygen;
(j) exhibits in silica gel thin layer chromatography an Rf value of 0.74 with the solvent system CHCl3-CH3OH (5:1 v/v) and exhibits in reverse phase silica gel thin layer chromatography an Rfvalue of 0.18 with the solvent system CH3CN-H20 (75:25 v/v);
(k) when dissolved in methanol at a concentration of 0.01356 g/l exhibits the following ultraviolet absorption maxima and absorptivities:: Xmax (nm) absorptivities
320 12.4
280 shoulder
253 25.1
210 25.5 with no significant change upon addition of acid or base;
(I) exhibits a high performance liquid chromatography retention time of 13.3 minutes with a C18 reversed phase silica gel column and the solvent system CH3CN-CH30H-0.1 M-CH3COONH4 (5:2:3 v/v);
(m) is effective in inhibiting the growth of various bacteria and fungi;
(n) induces prophage in lysogenic bacteria; and
(o) is effective in inhibiting the growth of P-388 leukemia, L-1210 leukemia, B16 melanoma and Lewis lung carcinoma in mice.
2. The antitumor antibiotic BBM-1675 A2 which in substantially purified form:
(a) appears as white crystals;
(b) is soluble in chloroform, ethyl acetate, acetone, ethanol and methanol, slightly soluble in benzene and water, and insoluble in n-hexane and carbon tetrachloride;
(c) gives a positive reaction with ferric chloride, Ehrlich and Tollen's reagents and a negative reaction in
Sakaguchi, ninhydrin and anthrone tests;
(d) exhibits an infrared absorption spectrum (KBr) substantially as shown in Figure 12;
(e) when dissolved in CDC13 exhibits a proton magnetic resonance spectrum substantially as shown in
Figure 13;
(f) has a melting point in the range of about 147-149"C; (g) has an optical rotation of [(X]D7 = - 179.4 (c 0.5, CHC13);; (h) has an apparent molecular weight of 1248 as determined by mass spectroscopy;
(i) has an approximate elemental composition of 52.71% carbon, 5.94% hydrogen, 3.94%-nitrogen, 9.39% sulfur and 28.01% (by difference) oxygen;
(j) exhibits in silica gel thin layer chromatography an Rf value of 0.71 with the solvent system CHCl3-CH3OH (5:1 v/v) and exhibits in reverse phase silica gel thin layer chromatography an Rf value of 0.21 with the solvent system CH3CN-H20 (75:25 v/v);
(k) when dissolved in methanol at a concentration of 0.02052 g/l exhibits the following ultraviolet absorption maxima and absorptivities:: Xmax (nm) absorptivities
320 12.2
282 16.3
282 26.2
214 25.8 with no significant change upon addition of acid or base;
(I) exhibits a high performance liquid chromatography retention time of 17.3 minutes with a C18 reversed phase silica gel column and the solvent system CH3CN-CH3OH-0.1 M CH3COONH4 (5:2:3 v/v);
(m) is effective in inhibiting the growth of various bacteria and fungi;
(n) induces prophage in lysogenic bacteria; and
(o) is effective in inhibiting the growth of P-388 leukemia, L-1210 leukemia, B16 melanoma and Lewis lung carcinoma in mice.
3. The antitumor antibiotic BBM-1675 A3 which:
(a) is soluble in chloroform, ethyl acetate, acetone, ethanol and methanol, slightly soluble in benzene and water, and insoluble in n-hexane and carbon tetrachloride;
(b) gives a positive reaction with ferric chloride, Ehrlich and Tollen's reagents and a negative reaction in
Sakaguchi, ninhydrin and anthrone tests;
(c) exhibits an infrared absorption spectrum (KBr) substantially as shown in Figure 3;
(d) when dissolved in CDCl3 exhibits a proton magnetic resonance spectrum substantially as shown in
Figure 7;
(e) has a melting point in the range of about 125-127"C; (f) has an optical rotation of [(X]D7 = - 161 (c 0.5, CHC13);; (g) has an approximate elemental composition of 54.55% carbon, 6.46% hydrogen, 3.73% nitrogen, 7.49% sulfur and 27.77% (by difference) oxygen;
(h) exhibits in silica gel thin layer chromatography an Rf value of 0.72 with the solvent system CHC13-CH30H (5:1 v/v) and exhibits in reverse phase silica gel thin layer chromatography an Rf value of 0.28 with the solvent system CH3CN-H20 (75::25 v/v);
(i) exhibits the following ultraviolet absorption maxima when dissolved in methanol, 0.01 N HCl-CH3OH and 0.01N NaOH-CH3OH
UV Amax nm (E1i'cm) 253 (286)
in methanol 282 (158)
320(122) UV Xmax nm (E1 cm) 253 (287) in0.01N HCI-CH30H 282(160)
320(126)
UV Xmax nm (Ea cm) 252 (280) in 0.01 N NaOH-CH3OH 283(162) 318(120); (j) exhibits a high performance liquid chromatography retention time of 8.0 minutes with a C18 reversed phase silica gel column and the solvent system CH3CN-CH3OH-0.1 M CH3COONH4 (5:2::3 v/v);
(k) is effective in inhibiting the growth of various bacteria and fungi;
(I) induces prophage in lysogenic bacteria; and
(m) is effective in inhibiting the growth of P-388 leukemia in mice.
4. The antitumor antibiotic BBM-1675 A4 which:
(a) is soluble in chloroform, ethyl acetate, acetone, ethanol and methanol, slightly soluble in benzene and water, and insoluble in n-hexane and carbon tetrachloride;
(b) gives a positive reaction with ferric chloride, Ehrlich and Tollen's reagents and a negative reaction in
Sakaguchi, ninhydrin and anthrone tests;
(c) exhibits an infrared absorption spectrum (KBr) substantially as shown in Figure 4;
(d) when dissolved in CDCl3 exhibits a proton magnetic resonance spectrum substantially as shown in
Figure 8;
(e) has a melting point in the range of about 123-1 26 C; (f) has an optical rotation of [(I]D7 - 176'(c0.5,CHCl3);; (g) has an approximate elemental composition of 54.65% carbon, 6.29% hydrogen, 3.51% nitrogen, 8.07% sulfur and 27.48% (by difference) oxygen;
(h) exhibits in silica gel thin layer chromatography an Rf value of 0.71 with the solvent system
CHCl3-CH3OH (5:1 v/v) and exhibits in reverse phase silica gel thin layer chromatography an Rf value of 0.78 with the solvent system CH3CN-H2O (75::25 v/v);
(i) exhibits the following ultraviolet absorption maxima when dissolved in methanol, 0.01 N HCl-CH3OH and 0.01 N NaOH-CH3OH
UV Xmax nm (E 1cm1%) 253 (257)
in methanol 282 (153)
320 (117) UV Xmax nm (E1i'c'm) 253 (258) in 0.01 N HCI-CH30H 282(155)
320(118)
UV Xmax nm (Ea /c m) 252 (266)
in 0.01 N NaOH-CH3OH 283 (160)
318(118);
(j) exhibits a high performance liquid chromatography retention time of 5.1 minutes with a C18 reversed phase silica gel column and the solvent system CH3CN-CH30H-0.1 M CH3COONH4 (5:2:3 v/v);
(k) is effective in inhibiting the growth of various bacteria and fungi;
(I) induces prophage in lysogenic bacteria; and
(m) is effective in inhibiting the growth of P-388 leukemia in mice.
5. The antitumor antibiotic BBM-1675 B1 which:
(a) is soluble in chloroform, ethyl acetate, acetone, ethanol and methanol, slightly soluble in benzene and water, and insoluble in n-hexane and carbon tetrachloride;
(b) gives a positive reaction with ferric chloride, Ehrlich and Tollen's reagents and a negative reaction in
Sakaguchi, ninhydrin and anthrone tests;
(c) has a melting point in the range of about 159-161 C;
(d) has an optical rotation of [a]027 - 171 (c 0.5, CHCl3);
(e) exhibits in silica gel thin layer chromatography an Rf value of 0.63 with the solvent system CHCl3-CH3OH (5:1 v/v) and exhibits in reverse phase silica gel thin layer chromatography an Rf value of 0.23 with the solvent system CH3CN-H2O (75::25 v/v);
(f) exhibits the following ultraviolet absorption maxima when dissolved in methanol, 0.01 N HCI-CH3OH and 0.01N NaOH-CH3OH
UV Xmax nm (Es c m) 253 (225)
in methanol 282 (140)
320(104)
UV #max nm (E1i'c'm) 253 (225)
in 0.01 N HCl-CH3OH 282 (140)
320 (105)
UV Amax nm (E1 c m) 252 (236)
in 0.01 N NaOH-CH3OH 283(141)
318(105);
(g) is effective in inhibiting the growth of various bacteria and fungi; and
(h) induces prophage in lysogenic bacteria.
6. The antitumor antibiotic BBM-1675 B2 which:
(a) is soluble in chloroform, ethyl acetate, acetone, ethanol and methanol, slightly soluble in benzene and water, and insoluble in n-hexane and carbon tetrachloride;
(b) gives a positive reaction with ferric chloride, Ehrlich and Tollen's reagents and a negative reaction in
Sakaguchi, ninhydrin and anthrone tests;
(c) has a melting point in the range of about 156-159 C;
(d) has an optical rotation of [st]jD7 - 122 (c 0.5, CHCl3); (e) exhibits in silica gel thin layer chromatography an Rf value of 0.60 with the solvent system
CHCl3-CH3OH (5:1 v/v) and exhibits in reverse phase silica gel thin layer chromatograpy an Rfvalue of 0.16 with the solvent system CH3CN-H20 (75::25 v/v);
(f) exhibits the following ultraviolet absorption maxima when dissolved in methanol,0.01N HCl-CH3OH and 0.01 N NaOH-CH3OH Us may nm (E11"c'm) 248 (212)
in methanol 279(141)
318(103)
UV Amax nm (En cm) 248 (210)
in 0.01N HCI-CH3OH 279 (140)
318(103) UV Xmax nm (E11,7c'm) 248 (233) in 0.01 N NaOH-CH3OH 278 (150) 318(110); (g) is effective in inhibiting the growth of various bacteria and fungi; and
(h) induces prophage in lysogenic bacteria.
7. The process for the production of the antitumor antibiotic BBM-1675 A1 which comprises cultivating a
BBM-1675 A1-producing strain of Actinomadura verrucosospora in an aqueous nutrient medium containing assimilable sources of carbon and nitrogen under submerged aerobic conditions until a substantial amount of BBM-1675 A1 is produced by said organism in said culture medium and then recovering BBM-1675 A1 from the culture medium.
8. The process according to Claim 7 wherein the BBM-1675 A1-producing organism has the identifying characteristics of Actinomadura verrucosospora strain H964-92 (ATCC 39334),Actinomadura verrucosospora strain Al 327Y (ATCC 39638), or a mutant thereof.
9. The process for the production of the antitumor antibiotic BBM-1675 A2 which comprises cultivating a
BBM-1675 A2-producing strain of Actinomadura verrucosospora in an aqeuous nutrient medium containing assimilable sources of carbon and nitrogen under submerged aerobic conditions until a substantial amount of BBM-1675 A2 is produced by said organism in said culture medium and then recovering BBM-1675 A2 from the culture medium.
10. The process according to Claim 9 wherein the BBM-1675 A2-producing organism has the identifying characteristics ofActinomadura verrucosospora strain H964-92 (ATCC 39334),Actinomadura verrucosospora strain Al 327Y (ATCC 39638), or a mutant thereof.
11. The process for the production of the antitumor antibiotic BBM-1675 A3 which comprises cultivating a
BBM-1675 A3-producing strain ofActinomadura verrucosospora in an aqueous nutrient medium containing assimilable sources of carbon and nitrogen under submerged aerobic conditions until a substantial amount of BBM-1675 A3 is produced by said organism in said culture medium and then recovering BBM-1675 A3 from the culture medium.
12. The process according to Claim 11 wherein the BBM-1675 A3-producing organism has the identifying characteristics of Actinomadura verrucosospora strain H964-92 (ATCC 39334),Actinomadura verrucosospora strain Al 327Y (ATCC 39638), or a mutant thereof.
13. The process for the production of the antitumor antibiotic BBM-1 675 A4 which comprises cultivating a
BBM-1675 A4-producing strain of Actinomadura verrucosospora in an aqueous nutrient medium containing assimilable sources of carbon and nitrogen under submerged aerobic conditions until a substantial amount of BBM-1675 A4 is produced by said organism in said culture medium and then recovering BBM-1675 A4 from the culture medium.
14. The process according to Claim 13 wherein the BBM-1675 A4-producing organism has the identifying characteristics of Actinomadura verrucosospora strain H964-92 (ATCC 39334),Actinomadura verrucosospora strain Al 327Y (ATCC 39638), or a mutant thereof.
15. The process for the production of the antitumor antibiotic BBM-1675 B1 which comprises cultivating a
BBM-1675 B1-producing strain of Actinomadura verrucosospora in an aqueous nutrient medium containing assimilable sources of carbon and nitrogen under submerged aerobic conditions until a substantial amount of BBM-1675 B1 is produced by said organism in said culture medium and then recovering BBM-1675 B1 from the culture medium.
16. The process according to Claim 15 wherein the BBM-1675 B1-producing organism has the identifying characteristics of A ctinomadura verrucosospora strain H964-92 (ATCC 39334), A ctinomadura verrucosospora strain Al 327Y (ATCC 39638), or a mutant thereof.
17. The process for the production of the antitumor antibiotic BBM-1675 B2 which comprises cultivating a
BBM-1675 B2-producing strain of Actinomadura verrucosospora in an aqueous nutrient medium cqntaining assimilable sources of carbon and nitrogen under submerged aerobic conditions until a substantial amount of BBM-1675 B2 is produced by said organism in said culture medium and then recovering BBM-1675 B2 from the culture medium.
18. The process according to Claim 17 wherein the BBM-1675 B2-producing organism has the identifying characteristics of Actinomadura verrucosospora strain H964-92 (ATCC 39334),Actinomadura verrucosospora strain A1327Y (ATCC 39638), or a mutant thereof.
19. A method for therapeutically treating an animal host affected by amicrnbial infection which comprises administering to said host an effective antimicrobial dose of BBM-1675 A1, BBM-l675 A2, BBM-1675 A3, BBM-1675 A4, BBM-1675 B1 or BBM-1675 B2.
20. A method for therapeutically treating an animal host affected by a malignant tumor, which comprises administering to said host an effective tumor-inhibiting dose of BBM-1675 A1, BBM-1675 A2, BBM-1675 A3, BBM-1675A4, BBM-1675 B, or BBM-1675 B2.
21. A pharmaceutical composition comprising an effective antimicrobial amount of BBM-1675 Al, BBM-1675 A2, BBM-1675 A3, BBM-1675 A4, BB-1675 B1 or BBM-1675 B2 in combination with a pharmaceutical carrier or diluent.
22. A pharmaceutical composition comprising an effective tumor-inhibiting amount of BBM-1675 A1,
BBM-1675 A2, BBM-1675 A3, BBM-1675 A4, BBM-1675 B1 or BBM-1675 B2 in combination with a pharmaceutical carrier or diluent.
23. A biologically pure culture of the microorganism Actinomadura verrucosospora strain H964-92 (ATCC 39334), said culture being capable of producing the antibiotic BBM-1675 in a recoverable quantity upon cultivation in an aqueous nutrient medium containing assimilable sources of carbon and nitrogen.
24. A biologically pure culture of the microorganism Actinomadura verrucosospora strain A1327Y (ATCC 39638), said culture being capable of producing the antibiotic BBM-1675 in a recoverable quantity upon cultivation in an aqueous nutrient medium containing assimilable sources of carbon and nitrogen.
25. Chemical compound BBM-1 675 Al obtained by cultivating Actinomadura verrucosospora strain
H964-92 (ATCC 39334) or A1327Y (ATCC 39638).
26. Chemical compound BBM-1 675 A2 obtained by cultivating Actinomadura verrucosospora strain H964-92 (ATCC 39334) or Al 327Y (ATCC 39638).
27. Chemical compound BBM-1 675 A3 obtained by cultivating Actinomadura verrucosospora strain
H-964-92 (ATCC 39334) or A1327\/ (ATCC 39638).
28. Chemical compound BBM-1 675 o obtained by cultivating Actinomadura verrucosospora strain H964-92 (ATCC 39334) or Al 327Y (ATCC 39638).
29. Chemical compound BBM-1675 B1 obtained by cultivating Actinomadura verrucosospora strain
H964-92 (ATCC 39334) or A1327Y (ATCC 39638).
30. Chemical compound BBM-1675 B2 obtained by cultivating Actinomadura verrucosospora strain
H964-92 (ATCC 39334) orA1327Y (ATCC 39638).
31. Chemical compound BBM-1675A1.
32. Chemical compound BBM-1675A2.
33. Chemical compound BBM-1675A3.
34. Chemical compound BBM-1675A4.
35. Chemical compound BBM-1675 B1.
36. Chemical compound BBM-1675 B2.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US49523183A | 1983-05-16 | 1983-05-16 |
Publications (3)
Publication Number | Publication Date |
---|---|
GB8412368D0 GB8412368D0 (en) | 1984-06-20 |
GB2141425A true GB2141425A (en) | 1984-12-19 |
GB2141425B GB2141425B (en) | 1986-12-03 |
Family
ID=23967812
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GB08412368A Expired GB2141425B (en) | 1983-05-16 | 1984-05-15 | Bbm-1675, a new antitumor antibiotic complex |
Country Status (28)
Country | Link |
---|---|
JP (2) | JPS59232094A (en) |
KR (2) | KR840008817A (en) |
AT (1) | AT393691B (en) |
AU (1) | AU569294B2 (en) |
BE (1) | BE899667A (en) |
CA (1) | CA1241282A (en) |
CY (1) | CY1465A (en) |
DE (1) | DE3418023A1 (en) |
DK (1) | DK163127C (en) |
ES (1) | ES8700267A1 (en) |
FI (1) | FI81114C (en) |
FR (1) | FR2547594B1 (en) |
GB (1) | GB2141425B (en) |
GR (1) | GR81581B (en) |
HK (1) | HK9889A (en) |
HU (1) | HU193928B (en) |
IE (1) | IE57444B1 (en) |
IL (1) | IL71824A (en) |
IT (1) | IT1175498B (en) |
KE (1) | KE3846A (en) |
LU (1) | LU85362A1 (en) |
NL (1) | NL8401572A (en) |
NZ (1) | NZ208013A (en) |
PT (1) | PT78590A (en) |
SE (1) | SE460364B (en) |
SU (1) | SU1344249A3 (en) |
YU (1) | YU43846B (en) |
ZA (1) | ZA843591B (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2586686A1 (en) * | 1985-08-27 | 1987-03-06 | Bristol Myers Co | NOVEL ANTIBIOTIC AND ANTITUMOR SUBSTANCES, PROCESS FOR THEIR OBTAINING AND ISOLATION; PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
EP0289030A2 (en) * | 1987-04-29 | 1988-11-02 | Bristol-Myers Squibb Company | Esperamicin derivatives, a process for preparing them and pharmaceutical compositions |
US4996305A (en) * | 1988-02-29 | 1991-02-26 | American Cyanamid Company | Process for producing the antibiotic and antitumor agents LL-E33288.epsilon.ε-Br |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GR78648B (en) * | 1982-07-26 | 1984-09-27 | Bristol Myers Co | |
CA2027601A1 (en) * | 1989-11-06 | 1991-05-07 | Koko Sugawara | Antitumor antibiotic bu-3983t |
CA3213700A1 (en) * | 2021-03-17 | 2022-09-22 | Nissui Corporation | Method of purification and purified products |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4195079A (en) * | 1979-01-31 | 1980-03-25 | Pfizer Inc. | New polycyclic ether antibiotic |
JPS56113791A (en) * | 1980-02-15 | 1981-09-07 | Kaken Pharmaceut Co Ltd | Novel antibiotic and its preparation |
GR78648B (en) * | 1982-07-26 | 1984-09-27 | Bristol Myers Co | |
US4539203A (en) * | 1984-11-13 | 1985-09-03 | Warner-Lambert Company | CL-1577D And CL-1577E antibiotic/antitumor compounds, their production and use |
-
1984
- 1984-05-01 NZ NZ208013A patent/NZ208013A/en unknown
- 1984-05-08 GR GR74646A patent/GR81581B/el unknown
- 1984-05-08 AU AU27791/84A patent/AU569294B2/en not_active Ceased
- 1984-05-08 CA CA000453762A patent/CA1241282A/en not_active Expired
- 1984-05-11 ZA ZA843591A patent/ZA843591B/en unknown
- 1984-05-11 FI FI841906A patent/FI81114C/en not_active IP Right Cessation
- 1984-05-14 ES ES532476A patent/ES8700267A1/en not_active Expired
- 1984-05-14 IL IL71824A patent/IL71824A/en unknown
- 1984-05-15 GB GB08412368A patent/GB2141425B/en not_active Expired
- 1984-05-15 SU SU843744582A patent/SU1344249A3/en active
- 1984-05-15 DE DE19843418023 patent/DE3418023A1/en active Granted
- 1984-05-15 DK DK239784A patent/DK163127C/en not_active IP Right Cessation
- 1984-05-15 IE IE1200/84A patent/IE57444B1/en not_active IP Right Cessation
- 1984-05-15 BE BE0/212942A patent/BE899667A/en not_active IP Right Cessation
- 1984-05-15 IT IT20928/84A patent/IT1175498B/en active
- 1984-05-15 LU LU85362A patent/LU85362A1/en unknown
- 1984-05-15 HU HU841877A patent/HU193928B/en not_active IP Right Cessation
- 1984-05-15 FR FR8407477A patent/FR2547594B1/en not_active Expired
- 1984-05-15 SE SE8402619A patent/SE460364B/en not_active IP Right Cessation
- 1984-05-16 PT PT78590A patent/PT78590A/en not_active IP Right Cessation
- 1984-05-16 KR KR1019840002636A patent/KR840008817A/en not_active Application Discontinuation
- 1984-05-16 AT AT0160984A patent/AT393691B/en not_active IP Right Cessation
- 1984-05-16 YU YU849/84A patent/YU43846B/en unknown
- 1984-05-16 NL NL8401572A patent/NL8401572A/en not_active Application Discontinuation
- 1984-05-16 JP JP59096758A patent/JPS59232094A/en active Granted
-
1988
- 1988-11-21 KE KE3846A patent/KE3846A/en unknown
-
1989
- 1989-02-02 HK HK98/89A patent/HK9889A/en unknown
- 1989-05-04 KR KR1019890006047A patent/KR920001366B1/en not_active IP Right Cessation
- 1989-07-21 CY CY1465A patent/CY1465A/en unknown
- 1989-08-24 JP JP1216009A patent/JPH02128693A/en active Granted
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2586686A1 (en) * | 1985-08-27 | 1987-03-06 | Bristol Myers Co | NOVEL ANTIBIOTIC AND ANTITUMOR SUBSTANCES, PROCESS FOR THEIR OBTAINING AND ISOLATION; PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
DE3629052A1 (en) * | 1985-08-27 | 1987-05-07 | Bristol Myers Co | ANTITUMOR ANTIBIOTICS |
EP0289030A2 (en) * | 1987-04-29 | 1988-11-02 | Bristol-Myers Squibb Company | Esperamicin derivatives, a process for preparing them and pharmaceutical compositions |
EP0289030A3 (en) * | 1987-04-29 | 1990-05-30 | Bristol-Myers Squibb Company | Esperamicin derivatives, a process for preparing them and pharmaceutical compositions |
US4996305A (en) * | 1988-02-29 | 1991-02-26 | American Cyanamid Company | Process for producing the antibiotic and antitumor agents LL-E33288.epsilon.ε-Br |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US4675187A (en) | BBM-1675, a new antibiotic complex | |
US4518589A (en) | BBM-2478 Antibiotic complex | |
US4524145A (en) | 4'-Deschlororebeccamycin pharmaceutical composition and method of use | |
EP0095154A1 (en) | Biologically active WS 6049 substances, a process for the production thereof and their pharmaceutical compositions | |
CA1230568A (en) | Antitumor antibiotic compound | |
GB2141425A (en) | BBM-1675, A new antitumor antibiotic complex | |
AU633826B2 (en) | Bu-3420t antitumor antibiotic | |
GB2050384A (en) | Antitumor antibacterial agents | |
US4360458A (en) | Antitumor antibacterial agents | |
US4708872A (en) | Antitumor antibiotic complex | |
US4626503A (en) | Antitumor agents LL-D49194α1, LL-D49194β1, LL-D49194β2, LL-D49194β3, LL-D49194γ, LL-D49194δ, LL-D49194ε, LL-D49194ξ, LL-D49194η, LL-D49194ω1, LL-D49194ω2, and LL-D49194ω3 | |
US4868117A (en) | BBM-1675, a new antitumor antibiotic complex | |
HARA et al. | THE KAPURIMYCINS, NEW ANTITUMOR ANTIBIOTICS PRODUCED BY STREPTOMYCES PRODUCING ORGANISM, FERMENTATION, ISOLATION AND BIOLOGICAL ACTIVITIES | |
US4572895A (en) | Process for preparing an antibiotic complex by culturing actinomyces strain ATCC 39417 | |
US4599310A (en) | Process for producing antitumor antibiotic compound | |
US4461831A (en) | Antitumor agents albacarcins V and M | |
EP0157203A2 (en) | Antitumor agents LL-D49194 alpha 1, LL-D49194 beta, LL-D49194 beta 2, LL-D49194 upsilon, LL-D49194 delta, LL-D49194 epsilon, LL-D49194 zeta, and LL-D49194 eta | |
US5116845A (en) | BU-3420T antitumor antibiotic | |
US4952572A (en) | BU-3420T antifungal antibiotic | |
CA2164618A1 (en) | Compound ge3 | |
CH663155A5 (en) | Antitumour antibiotics | |
EP0657467A1 (en) | Antitumor antibiotics |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PCNP | Patent ceased through non-payment of renewal fee |
Effective date: 19960515 |